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ABSTRACT.  Chikungunya virus (CHIKV) causes an arboviral disease and was first recognized 
in epidemic form in East Africa in 1952–1953.  The virus is primarily transmitted through 
mosquitoes and the resulting disease, chikungunya fever, is found in nearly 40 countries.  
Neither an effective vaccine nor a specific antiviral drug exists for treatments of Chikungunya 
fever.  Thus 25 new triply conjugated compounds of uracil−coumarin−arene were designed and 
synthesized as potential inhibiting agents.  Their chemical structures were determined 
unambiguously by spectroscopic methods, including single-crystal X-ray diffraction 
crystallography.  The three nuclei in these conjugates were connected by specially designed 
−SCH2− and −OSO2− joints.  Five of these new conjugates were found to inhibit CHIKV Vero 
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cells with significant potency (EC50 = 10.2–19.1 µM) and showed low toxicity (CC50 = 75–178 
µM).  The selective index values were 9.3–11.5 for three conjugates.  By analysis of the data 
from the anti-viral assays, the structure–activity relationship is derived on the basis of the nature 
of the uracil nucleus, the joint between the nuclei, and the functional group attached to the arene 
nucleus. 
Introduction  
 Chikungunya (CHIK) fever was first recognized in an epidemic form in East Africa in 
1952–19531 and is mainly transmitted by mosquitoes.  A number of CHIK cases have emerged 
in more than 40 countries in Africa and Asia over the past half century.2,3  Chikungunya virus 
(CHIKV) belongs to the family Togaviridae and the genus Alphavirus, which includes enveloped 
and positive single-stranded RNA viruses.1,4  Unfortunately, the pathogenesis of CHIK disease 
still remains unknown.  Presently, there is neither an effective vaccine nor a specific antiviral 
drug available for this disease.5  Consequently, the development of drugs with activity against 
CHIKV is becoming a global concern of the utmost importance. 
 S-Adenosyl homocysteine hydrolase, inositol monophosphate dehydrogenase, and 
orotidine 59-phosphate decarboxylase are broad-spectrum antiviral agents.  Nevertheless, their 
application to against CHIKV infection is inadequate.6  Several chemical compounds have been 
reported to exhibit weak anti-CHIKV activity.  They include apigenin,6 6-azauridine,6 
chloroquine,7 chrysin,6 (5,7-dihydroxy)flavones,6 interferon, mycophenolic acid,8 prothipendyl,6 
ribavirin,9 silibin,6 etc.  In 2011, arbidol and its two derived metabolites were tested in vitro on 
the CHIKV by use of two cell lines in pre- and post-infection conditions.10  Arbidol was found to 
have an IC50 of 12.2 µM.  In 2012, D’Hooghe et al.11 reported that two purine-β-lactam hybrids 
possess anti-CHIKV activity with EC50 of 17.11 and 13.01 µM, respectively, and selectivity 
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indices (SIs) of >5.75 and >4, respectively.  Additionally, purine-aminopropanol exhibits an 
EC50 of 11.51 µM with an SI > 6.15.   In 2013, Bassetto et al.12 reported an EC50 of 5 µM with an 
SI of 14 for benzylidene(cyclopropane)carbohydrazide, which inhibited the virus-induced 
cytopathic effect. 
 Many efforts have sought to identify novel inhibitors of CHIKV from natural sources.  
For example, Bourjot et al.13 performed a phytochemical study on the leaves of Anacolosa 
pervilleana (a Madagascan plant) in a virus-cell-based assay.  They isolated the triterpenoids 
lupenone and β-amyrone, which show moderate anti-CHIKV activity.  
  The aim of this study was to develop new leads that inhibit emerging viruses, including 
CHIKV.  Accordingly the molecular structure 1 was designed, from which a new compound 
library would be established.  The resultant compounds were primarily composed of a “triply” 
conjugated skeleton of uracil–coumarin–arene; three nuclei therein were linked through 
thiomethylene (–SCH2–) and sulfo (–OSO2–) joints.  In some of these triply conjugated 
compounds, the –OSO2– joint was replaced by –OCH2–.  The structure–activity relationship 
(SAR) would be established on the analysis of the derivatives containing various substituents on 
the uracil and the arene nuclei.  
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 The uracil, thymine (i.e., 5-methyluracil), and benzouracil (i.e., quinazolinone) moieties 
exist in many biologically active compounds.14   Recently, Wang et al.15 revealed that the 
substituents on the C-5 and C-6 positions (i.e., R1 and R2, respectively, in 1) of the uracil nucleus 
are important to anti-viral activity.  Abdel–Aal et al.16 synthesized compounds with two 
hydrophobic residues at the C-5 and C-6 positions.  These compounds exhibited potent activity 
against hepatitis B virus (HBV).  Kumar et al.17 prepared various 5-substituted uracils containing 
a 1-[(2-hydroxyethoxy)methyl]glycosyl moiety at the N-1 position.  These compounds show 
potent in vitro activity toward both chronically infected primary duck hepatocytes and a human 
HBV DNA transfected human hepatoblastoma cell line (HepG2 2.2.15).  Among acyclic 
pyrimidine nucleosides, substituents at the C-5 position are influential determinants against duck 
HBV, wild-type human HBV, and lamivudine-resistant HBV in vitro at non-cytotoxic 
concentrations.  Ordonez et al.18 found that the introduction of a substituent at the C-6 position of 
uracil resulted in elevated anti-HIV-1 activity. 
 Benzouracil and its derivatives have been extensively studied because of their wide range 
of pharmacological activities.  Medicinally, many of them display anti-cancer,19 anti-
convulsant,20 anti-depressant,21 anti-inflammatory,22 anti-fungal,23 anti-HIV,24 anti-microbial,25 
anti-ulcer,26 analgesic,27 hypolipidemic,28 or immunotropic activity.29  Some of them act as 
inhibitors of thymidylate synthase,30 poly(ADP-ribose) polymerase (PARP),31 or protein tyrosine 
kinase.32  Alogliptin, which contains a benzouracil moiety, is a potent selective inhibitor of 
serine protease.33  Moreover, the benzouracil nucleus is widely present in biologically active 
natural products.34  
 Results from recent studies indicate the prominent activity of coumarins toward 
proteases.  The two hydroxyl groups attached to the nucleus and the α,β-unsaturated carbon to 
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carbon double bond therein make coumarin as one of the most potent protease inhibitors.35  
Coumarin  type molecules also display high inhibitory activity towards various serine 
proteases, human leukocyte elastase, porcine pancreatic elastase, thrombin, urokinase, and 
human plasmin.36  Additionally, isocoumarins are effective as mechanism-based inhibitors of 
serine proteases.36 Coumarins conjugated with various benzimidazoles37 or heterobicycles38 have 
been synthesized by our research group recently.  These conjugates exhibit appealing anti-viral 
activity and become promising leads for further development.     
 The connection of a benzimidazole nucleus to a coumarin nucleus produces a conjugated 
compound, which exhibit activity against hepatitis C virus (HCV).37  Replacement of the 
benzimidazole nucleus with nucleobases results in the related conjugates with enhanced anti-
HCV acitivity.39  Anti-HCV compound libraries have been established and include conjugated 
compounds, in which coumarin moieties are in connection with various heterocycles, including 
benzothiazole,38 benzoxazole,38 and imidazopyridine.40  These findings indicate the importance 
of the thiomethylene joint for the connection. 41 
 Compounds containing a sulfo (R–OSO2–R’) joint have been identified as potent 
protease inhibitors.42,43  The reaction of sulfonate compounds with the hydroxyl site of an active 
protease residue can form a stable enzyme derivative.44  Substantial hypoxic selectivity and 
antitumor activity have been also observed for many sulfonates.45  Nitrophenyl esters of 
benzenesulfonic acid and phenylmethanesulfonic acid bearing various positively charged groups 
on the benzene ring act as inactivators of trypsin-like proteases.44  For example, p-nitrophenyl  
p-(amidinothiomethyl)benzenesulfonate inactivates thrombin.  As five-membered cyclic 
sulfonates, sultones are highly reactive toward chymotrypsin.44  2-Hydroxy-3,5-dinitro-R-
toluenesulfonic acid sultone and o-hydroxy-R-toluenesulfonic acid sultone react with α-
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chymotrypsin rapidly to form catalytically inactive sulfonyl enzymes that decompose slowly 
over time.  Recently, Udommaneethanakit et al.46 reported the inhibition of avian influenza A 
virus with sulfonate drugs, such as oseltamivir, peramivir–sulfonate, and zanamivir.  Moreover, 
Cravatt, Sorensen, et al.47 successfully identified the targets of sulfonate ester probes that belong 
to several mechanistically distinct enzyme classes.  They include dehydrogenases, epoxide 
hydrolases, glutathione S-transferases, sugar kinases, and transglutaminases.  These sulfonate 
ester labeling events occur in enzyme active sites that exhibit heat sensitivity, competition 
between the substrates and cofactors, and dependency on endogenous activators.48  They also 
discovered the potent and selectively reversible inhibitors of enzymes in complex proteomes and 
analyzed the compounds in competitive screens using a class of probes with a sulfonate ester 
group.  These sulfonate probes profile several distinct enzyme classes, including aldehyde 
dehydrogenases, enoyl CoA-hydratases, and glutathione S-transferases.49 
 Herein we report the scope of uracil–coumarin–arene conjugates as an unprecedented 
class of anti-CHIKV agents.  Furthermore, various substituents were linked to the uracil and 
arene nuclei.  In total, 25 compounds with the common skeleton 1 were synthesized, five of 
which exhibited significant anti-CHIKV activity.  Accordingly, their structure–activity 
relationship was deduced. 
Results and Discussion 
 For the synthesis of “triply” conjugated compounds with the scaffold 1 (i.e., uracil–
coumarin–arenes), three challenges had to be overcome.  First, the labile sulfo group connecting 
the coumarin and arene moieties had to remain intact throughout the synthetic steps.  Second, the 
conditions to form the S−CH2 single bond had to be mild enough to maintain the bond.  Third, 
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the reagents could not induce a Michael addition to the α,β-unsaturated ester group or ring-
opening of the δ-lactone moiety in 1.  Given these three concerns, the sequential synthetic routes 
shown in Schemes 1−4 were developed.  
Synthesis of Doubly Conjugated (4-Chloromethyl)coumarin–Arene Intermediates (Scheme 
1).  For the construction of the triply conjugated scaffold 1, the intermediates 
(arenesulfonyl)coumarins 6 and benzylcoumarins 8 were prepared by use of resorcinol (2) and 4-
chloroethyl acetoacetate (3) as the starting materials.  Through the Pechmann condensation50 in 
the presence of p-toluenesulfonic acid as the catalyst in dry toluene, 7-hydroxycoumarin 4 was 
generated at an elevated temperature.  Its sulfonylation with benzenesulfonyl chlorides 5 in the 
presence of K2CO3 (anhydrous) at 50–55 °C afforded the corresponding 7-O-sulfonylated 
coumarins 6 in good yields.  Under similar reaction conditions, 7-O-benzylated coumarins 8 
were obtained by benzylation of 7-hydroxycoumarin 4 with the benzyl bromides 7.  Accordingly, 
two series of coumarins, 6 and 8, were obtained, in which the substituents R included Me, F, Cl, 
Br, Me, and NO2 in the ortho or para position. 
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Syntheses of coumarin derivatives with benzenesulfonyl or benzyl fragments 
 Syntheses of Triply Conjugated Uracil−Coumarin−Arene Targets and Their 
Analogs (Schemes 2 and 3).  The coupling of 2-thiobenzouracil 9 with various  
(4-chloromethyl)coumarins 6 to generate uracil–coumarin–arene conjugates 10a–e were 
performed under different alkaline conditions.  At elevated temperatures (>65 °C), the sulfo 
group (i.e., –OSO2–) in 10 was destroyed.  The use of bases, such as (N,N-
diisopropyl)ethylamine and (4-dimethylamino)pyridine for the generation of a nucleophile from 
2-thiobenzouracil 9 resulted in problems with either ring opening of the coumarin moiety or 
substitution at the allylic chloride or both.  Workup conditions with appropriate pH values 
between 10.0 and 11.5 were found to be critical for the maintenance of the S–CH2 single bond in 
10.  Accordingly, the desired triply conjugated compounds 10a–e were synthesized through 
alkylation at the C-2 thione center of 9, which resulted from the presence of a preferred negative 
charge on the exocyclic sulfur atom instead of the exocyclic oxygen atom.51  This S-alkylation 
was carried out at 40 °C in the presence of anhydrous K2CO3 in THF or ethanol.  A slightly 
alkaline solution with pH 8.0–9.0 was then applied during the workup.  Accordingly, the triply 
conjugated compounds 10a–e, 12a–e, and 14a–e, which contained nuclei of benzouracil, 
methyluracil, and uracil, were obtained in 81–94% yields (see Scheme 2).  Potential by-products 
from the additions of uracil to the lactone carbonyl group of coumarins 6 or to the α,β-
unsaturated carbon to carbon double bond were not detected. 
 Under similar reaction conditions, the triply conjugated compounds 15a–d, 16a–d, and 
17a–d with –SCH2– and –OCH2– joints were also obtained as shown in Scheme 3.  The 
corresponding doubly conjugated compounds 18–20 without the arene moiety were produced 
(see Scheme 4) as the reference compounds for deduction of the structure–activity relationship.  
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Scheme 2. Synthesis of the benzouracil−, thymine−, and uracil−coumarin−arene conjugates 
bearing the –SCH2– and –OSO2– joints 
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Scheme 3. Synthesis of uracil−coumarin−arene conjugates bearing the –SCH2– and –OCH2– 
joints 
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Scheme 4. Syntheses of doubly conjugated compounds containing benzouracil−, thymine–, and 
uracil–coumarin nuclei 
Identification of the Structures of Conjugated Compounds.  The structures of all new 
compounds were determined according to their spectroscopic characteristics.  For example, the 
mass spectrum of 14a from FABMS analysis exhibited 442.0290, which indicates a molecular 
formula of C20H14N2O6S2 with a theoretical value of 442.0293.  Its 13C NMR spectrum showed 
18 signals, which is in accordance with the theoretical number.  Resonance at δ 164.91 and 
154.88 ppm were assigned to the two C=O carbons; resonance at δ 159.61 and 29.99 ppm were 
assigned to the N=C−N and the SCH2 carbons, respectively. 
 Furthermore, the 1H NMR spectrum of 14a displayed two characteristic singlets at δ
4.48 and 6.58 ppm for the SCH2 and H-3´ protons, respectively.  A multiplet appeared at 
δ 6.23−6.21 ppm for the H-5 proton. Its IR spectrum showed two medium absorption bands at 
1718 and 1653 cm–1, which were attributed to the two carbonyl stretching vibrations.39  A 
medium absorption band at 1353 cm−1 was attributed to the S=O stretching vibration. 
 These spectroscopic data did not provide sufficient information to establish the 
connection of the uracil nucleus to the coumarin nucleus through the C=O or the C=S site.  
Therefore, molecular framework of the uracil−coumarin−arene conjugate 14a was determined by 
single X-ray diffraction analysis (Figure).  Its monoclinic crystals possessed the space group P1 
21/c 1 with a = 21.413(4) Å, b = 6.2583(12) Å, c = 14.392(3) Å, and  = 90°,  = 99°, and γ = 
90°.  These results indicate that the alkylation took place unequivocally at the C-2 position of the 
uracil and thus confirm the formation of an NCS−CH2 single bond.   
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Figure.  Molecular frameworks:  ORTEP diagram of 14a obtained by X-ray diffraction analysis. 
 The 13C NMR spectra of all triply conjugated compounds exhibited the expected number 
of carbon peaks, with the exception of compound 12e.  Its spectrum exhibited one less carbon 
resonance than expected because the peaks associated with the two quaternary carbons C-7´ and 
C-2´´ were overlapped at δ 150.19 ppm.   
Evaluation of the Anti-CHIKV Activity and Measurement of Lipophilicity 
 The biological activity of the conjugated compounds against the CHIKV (899 strain) in 
Vero cells subtype A was evaluated according to established methods.12   The compound 
concentration that inhibited virus replication by 50% (i.e., EC50) and that reduced host cell 
metabolism by 50% (i.e., CC50) were calculated from the dose-response curves.  Subsequently, 
these values were used to calculate the selectivity index (i.e., SI = CC50/EC50), which is a 
measure for the therapeutic window of the compound in an assay system.  Compounds were only 
considered as selective inhibitors in the replicon assay when virus RNA replication was 
significantly inhibited (>70%) at concentrations that did not adversely affect the host cell 
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metabolism.  The antiviral effect of compounds that adversely affected the host cell metabolism 
was likely as a result of a pleiotropic or non-specific effect on the host cell. 
 Among these 25 new conjugated compounds, 10a, 10b, 10e, 12e, and 14e inhibited 
CHIKV Vero cells with appealing potency (Table) with EC50 values ranging from 10.2 to 19.1 
µM.  They displayed a significant window of selectivity with SI values between 5.8 and 11.5. 
 Molecular lipophilicity, usually quantified as log P, of chemical entities plays an 
important role in the development of drug leads52 and is related to the structure–activity 
relationship.  The apparent partition coefficient (P) is the ratio of the concentration of conjugated 
compounds in n-octanol to the concentration of the same species in the aqueous phase.  The log 
P coefficient is one of the principal parameters for the estimation of lipophilicity/hydrophobicity 
of chemical compounds and determines their pharmacokinetic properties.  Consequently, the 
‘‘shake–flask method’’ was applied by use of n-octanol and water to obtain the log P values53 of 
the triply conjugated compounds 10a,b,e, 12b,e, 14b, and 15a,b as well as the doubly conjugated 
compound 18 for comparison (Table). 
 The log Ps of thousands of drugs and potential drugs have been measured.  Nevertheless, 
only a limited open pilot study is carried out with chloroquine as a treatment for chronic 
Chikungunya arthritis on patients and is reported an improvement in symptoms such as morning 
stiffness.  Results from many reports indicate antiviral activity of chloroquine in vitro, in 
particular the inhibition of the CHIKV-related virus Mayaro.  This led to a clinical trial in La 
Re ́union Island to test the efficiency of chloroquine in vivo.7  However, chloroquine with a log P 
value of 5.3 does not follow the Lipinski rule of lipophilicity.  Poor absorption or permeation is 
more likely to occur when the calculated log P is greater than 5.54 
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 The data presented in Table indicate that the molecular lipophilicity of compounds 10–18 
fell into the range of –2.74 to 3.57, which follows the Lipinski rule for lipophilicity.54  The log P 
value of 2.13 for benzouracil sulfonate 10b with promising EC50 and SI values was less than that 
(5.3) for chloroquine.  
Table.  Inhibitory effects of conjugated compounds on CHIKV (899 strain) in Vero cells subtype 
A and their lipophilicity 
conjugates CC50[a] (µM) EC50[b] (µM) SI[c] log P 
10a 178 19.1 9.3 1.91 
10b 117 10.2 11.5 2.13 
10c 30 18.4 1.6 − 
10d 117 54.5 2.2 − 
10e 144 17.2 8.8 −1.07 
12a 126            58 2.2 − 
12b 114 26.4 4.3 0.611 
12c      86.4          116 − − 
12d −        >199 − − 
12e 107 19.0 5.6 −2.60 
14a −   57.4 − − 
14b 60.2    23.1 2.6 0.467 
14c              111              128          − − 
14d −        >205 − − 
14e 75.2            13 5.8 −2.74 
15a − >45.2 − 3.35 
15b              102        >219 − 3.57 
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16a −        >246 − − 
16b −          >48 − − 
16c             104 45.1 2.3 − 
17a −        >255 − − 
17d 13.8 4.6 3.0 − 
18           >284 192    >1.5 1.32 
19 − >316 − − 
20 − >331 − − 
 [a] The concentration of a compound with an adverse effect of 50% was observed on the host cell 
metabolism, as determined by the MTS method.  [b] The concentration of a compound at which 
virus replication was inhibited by 50% was observed, as determined by real-time quantitative 
RT–PCR. [c] Selectivity index.  
Structure−Activity Relationship:  Essential Moieties and Functional Groups.  In this new 
compound library, the triply conjugated compounds primarily contain three primary components:  
coumarin, uracil (including thymine and benzouracil), and arene (with different substituents, 
including Me, F, Cl, Br, Me, and NO2).  Meanwhile, a –SCH2– unit was used to link the uracil 
and the coumarin moieties; then a –OSO2– or –OCH2– unit was used to link the coumarin and 
arene moieties.  Through analysis of their anti-CHIKV activities and lipophilicities shown in 
Table, we deduce the following SAR by scrutinizing their EC50, CC50, SI, and log P values. 
 (1) Introduction of a benzenesulfonyl moiety to the thiomethylene-linked benzouracil–
coumarin conjugates led to triply hybrid compounds 10, which exhibited desirable anti-CHIKV 
activity.  Successful examples include 10a, 10b, and 10e with EC50 = 10.2–19.1 µM and SI = 
8.8–11.5.  The benzouracil–coumarin conjugates without a benzenesulfonyl moiety (e.g., 18–20) 
did not exhibit significant activity. 
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 (2) The triply conjugated compounds with the –OSO2– joint between coumarin–arene 
moieties exhibited greater anti-CHIKV activity than those with the –OCH2– joint (cf. 10a versus 
15a, 10b versus 15b, 12a versus 16a, 12b versus 16b, and 14a versus 17a).      
 (3) Addition of the Me electron-releasing group to the benzenesulfonyl moiety often 
increased the potency and SI value by a factor of 1.2–2.3 (cf. 10b, 12b, and 14b versus 10a, 12a, 
and 14a, respectively).  Compounds with the NO2 electron-withdrawing group at the ortho 
position showed greater activity (>3.16–15.8 fold) than those with the same group at the para 
position (cf. 10e > 10d, 12e > 12d, and 14e > 14d). 
 (4)  The conjugated compounds with the benzouracil moiety showed a higher selectivity 
(i.e., the SI value) than those with thymine and uracil moieties (cf. 10a–e  > 12a–e  > 14a–e).  As 
the size of this moiety increases (i.e., benzouracil > thymine > uracil), the inhibition of CHIKV 
generally increases.  This relationship also exist with the lipophilicity of the conjugates as 
exhibited by the log P values shown in Table (cf. 10b  > 12b  > 14b and 10e  > 12e  > 14e). 
 (5)  Anti-CHIKV activity (as reflected by the EC50 value) was greater for the triply 
conjugated compounds with higher lipophilicity (as indicated by a lager value of log P).  For 
example, the methylated 10b (EC50 = 10.2 µM, log P = 2.13) was more active than the parent 
compound 10a (EC50 = 19.1 µM, log P = 1.91).  Compound 10b containing a benzouracil moiety 
was more potent and lipophilic than compound 12b containing a thymine moiety (EC50 = 26.4 
µM, log P = 0.611) and compound 14b containing a uracil moiety (EC50 = 23.1 µM, log P = 
0.467).  Similar phenomena were observed among compounds 10e, 12e, and 14e. 
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Conclusions 
 For the development of new compounds with anti-CHIKV activity, a series of triply 
conjugated uracil−coumarin−arenes were designed and synthesized.  Among 25 new compounds 
produced, five conjugates were found to inhibit CHIKV (899 strain) in Vero cells subtype A.  
Promising results were associated with the five compounds 10a, 10b, 10e, 12e, and 14e, which 
impeded CHIKV replication at EC50 values of 19.1, 10.2, 17.2, 19.0, and 13.0 µM, respectively.   
Moreover, guidelines of SAR were deduced by the analysis of the scaffold of the conjugated 
compounds 10, 12, 14–20 and their anti-CHIKV activities.  The coumarin moiety in the 
conjugated compounds was required for antiviral activity.  This central moiety was attached to a 
pyrimidine nucleus at the C-2 position through a –SCH2– joint on one side and an arene group 
through a –OSO2– joint on the other side.  The triply conjugated scaffold, as in compounds 10, 
provided higher anti-CHIKV activity than other analogs such as conjugates 15–20.  These 
guidelines will be useful for the future design and synthesis of new conjugated compounds.  The 
mode of actions of these new leads towards enzymes associated with CHIKV is currently under 
investigation and the results will be reported in due course.  
Experimental 
General.  All reactions were carried out in oven-dried glassware (120 °C) under an atmosphere 
of nitrogen unless as indicated otherwise.  Acetone, dichloromethane, ethanol, ethyl acetate, 
hexanes, methanol, and THF were purchased from Mallinckrodt Chemical Co.  Ethyl acetate was 
dried and distilled from CaH2.  Tetrahydrofuran was dried by distillation from sodium and 
benzophenone under an atmosphere of nitrogen.  2-Thiouracil and triethylamine was purchased 
from Tedia Company Inc.  5-Methyl-2-thiouracil and quinazolinone were purchased from Alfa 
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Aesar Chemical Co.  Benzyl bromide, 4-bromobenzyl bromide, 4-chlorobenzyl bromide, and 4-
methylbenzyl bromide were purchased from Acros Organics.  Benzenesulfonyl chloride, p-
toluenesulfonyl chloride, 4-methylbenzenesulfonyl chloride, 4-fluorobenzenesulfonyl chloride,  
4-nitrobenzenesulfonyl chloride, and 2-nitrobenzenesulfonyl chloride were purchased from 
Sigma-Aldrich Chemical Co.  Potassium carbonate and p-toluenesulfonic acid were purchased 
from Showa Chemical Co.  7-Hydroxycoumarin was prepared according to the reported 
methods.50 
Melting points were obtained with a Fargo MP-2D melting point apparatus.  Analytical 
thin layer chromatography (TLC) was performed on precoated plates (silica gel 60 F-254), 
purchased from Merck Inc.  High performance liquid chromatography (HPLC) was performed 
on two Waters 515 HPLC pumps equipped with a Waters 2489 UV/visible detector and a 
Thermo 5 µm Hypersil ODS (250 mm 4.6 mm i.d.).  Purity of all compounds was >98.0%, as 
checked by HPLC. 
Infrared (IR) spectra were measured on a Perkin–Elmer Model Spectrum 100 
spectrophotometer.  Absorption intensities are recorded by the following abbreviations:  s = 
strong; m = medium; and w = weak.  Proton NMR spectra were obtained on a Varian Mercury-
400 (400 MHz) spectrometer or Bruker AC-400 (400 MHz) spectrometer by use of chloroform-d 
(CDCl3) and dimethylsulfoxide-d6 (DMSO-d6) as the solvents.  Proton NMR chemical shifts 
were referenced to residual protonated solvents (δ 7.24 for chloroform and δ 2.49 for 
dimethylsulfoxide).  Carbon-13 NMR spectra were obtained on a Varian Mercury-400 (100 
MHz) spectrometer by use of chloroform-d (CDCl3) and dimethylsulfoxide-d6 (DMSO-d6) as the 
solvents.  Carbon-13 chemical shifts are referenced to the center of the CDCl3 triplet (δ 77.0 
ppm) and DMSO septet (δ 39.5 ppm).  Multiplicities are recorded by the following 
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abbreviations:  s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J, coupling constant 
(hertz).  High-resolution mass spectra were obtained by means of a JEOL JMS-700 mass 
spectrometer.  
Standard Procedure 1 for the Preparation of Couamrin Intermediates 6 and 8.  To a 
solution containing 7-hydroxycoumarin50 (4, 1.0 equiv) in anhydrous acetone (6.0–15 mL) was 
added potassium carbonate (1.5 equiv) and a sulfonyl chloride 5 or benzyl bromide 7 (1.2 equiv).  
After the reaction mixture was stirred at 55 °C for 1.0−1.5 h, it was cooled down to room 
temperature.  Inorganic solids were filtered off and the filtrate was concentrated under reduced 
pressure to afford the residue.  It was then purified by use of gravity column chromatography on 
silica gel (various ratio of EtOAc to hexanes) to give the desired coupled derivatives 6 or 8. 
4-(Chloromethyl)-2-oxo-2H-chromen-7-yl Benzenesulfonate (6a).55  The Standard Procedure 
1 was followed by use of 4 (500.4 mg, 2.376 mmol, 1.0 equiv) in acetone (15 mL), K2CO3 (492.6 
mg, 3.564 mmol, 1.5 equiv), and benzenesulfonyl chloride (5a, 503.5 mg, 2.851 mmol,  
1.2 equiv).  After workup, the residue was purified by use of gravity column chromatography on 
silica gel (20% EtOAc in hexanes) to give the desired coumarin 6a (728.1 mg, 1.996 mmol) in 
84% yield as white solids.  The spectroscopic data were found to be in accordance with literature 
data.55  
4-(Chloromethyl)-2-oxo-2H-chromen-7-yl 4-Methylbenzenesulfonate (6b). The Standard 
Procedure 1 was followed by use of 4 (500.1 mg, 2.374 mmol, 1.0 equiv) in acetone (15 mL), 
K2CO3 (492.3 mg, 3.562 mmol, 1.5 equiv), and 4-methylbenzenesulfonyl chloride (5b, 543.2 mg, 
2.849 mmol, 1.2 equiv).  After workup, the residue was purified by use of gravity column 
chromatography on silica gel (20% EtOAc in hexanes) to give the desired coumarin 6b  
(710.3 mg, 1.947 mmol) in 82% yield as white solids:  mp (recrystallized from CH2Cl2) 
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130.3−131.2 °C; 1H NMR (CDCl3, 400 MHz) δ 7.72 (d, J = 8.0 Hz, 2 H, 2 × ArH), 7.61 (d,  
J = 8.8 Hz, 1 H, H-5), 7.33 (d, J = 8.0 Hz, 2 H, 2 × ArH), 7.11−7.08 (m, 1 H, H-6), 6.89 (d,  
J = 2.4 Hz, 1 H, H-8), 6.52 (s, 1 H, H-3), 4.60 (s, 2 H, CH2Cl), 2.45 (s, 3 H, CH3); 13C NMR 
(CDCl3, 100 MHz) δ 159.46 (C=O), 154.19, 151.80, 148.84, 146.12, 131.76, 130.06, 128.38, 
125.43, 119.03, 116.09, 115.85, 111.26, 41.02 (CH2Cl), 21.73 (CH3); IR (neat) 1734 (s, C=O), 
1376 (m, S=O), 1177 (s), 1121 (s), 996 (s), 755 (s) cm–1; HRMS (FAB) calcd for (C17H13ClO5S):  
364.0172; found 364.0179. 
4-(Chloromethyl)-2-oxo-2H-chromen-7-yl 4-Fluorobenzenesulfonate (6c).  The Standard 
Procedure 1 was followed by use of 4 (400.2 mg, 1.900 mmol, 1.0 equiv) in acetone (15 mL), 
K2CO3 (393.9 mg, 2.850 mmol, 1.5 equiv), and 4-fluorobenzenesulfonyl chloride (5c, 443.7 mg, 
2.280 mmol, 1.2 equiv).  After workup, the residue was purified by use of gravity column 
chromatography on silica gel (20% EtOAc in hexanes) to give the desired coumarin 6c  
(581.6 mg, 1.577 mmol) in 83% yield as white solids:  mp (recrystallized from CH2Cl2) 
133.5−134.5 °C; 1H NMR (CDCl3, 400 MHz) δ 7.91−7.87 (m, 2 H, 2 × ArH), 7.64 (d,  
J = 8.8 Hz, 1 H, H-5), 7.26−7.22 (m, 2 H, 2 × ArH), 7.08 (dd, J = 8.8, 2.2 Hz, 1 H, H-6), 6.97 (d, 
J = 2.2 Hz, 1 H, H-8), 6.55 (s, 1 H, H-3), 4.62 (s, 2 H, CH2Cl); 13C NMR (CDCl3, 100 MHz) δ 
167.83 (C−F), 165.26 (C=O), 159.61, 154.58, 151.80, 149.00, 131.68, 131.58, 125.87, 119.12, 
117.34, 117.11, 116.58, 116.37, 111.58, 41.29 (CH2Cl); IR (neat) 1734 (s, C=O), 1381 (m, S=O), 
1260 (s, C−F), 764 (s) cm–1; HRMS (FAB) calcd for (C16H10ClFO5S):  367.9922; found 
367.9926. 
4-(Chloromethyl)-2-oxo-2H-chromen-7-yl 4-Nitrobenzenesulfonate (6d).55  The Standard 
Procedure 1 was followed by use of 4 (500.2 mg, 2.375 mmol, 1.0 equiv) in acetone (15 mL), 
K2CO3 (492.4 mg, 3.562 mmol, 1.5 equiv), and 4-nitrobenzenesulfonyl chloride (5d, 631.6 mg, 
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2.850 mmol, 1.2 equiv).  After workup, the residue was purified by use of gravity column 
chromatography on silica gel (20% EtOAc in hexanes) to give the desired coumarin 6d  
(778.2 mg, 1.966 mmol) in 83% yield as light yellow.  The spectroscopic data were found to be 
in accordance with literature data.55  
4-(Chloromethyl)-2-oxo-2H-chromen-7-yl 2-Nitrobenzenesulfonate (6e).  The Standard 
Procedure 1 was followed by use of 4 (500.2 mg, 2.375 mmol, 1.0 equiv) in acetone (15 mL), 
K2CO3 (492.4 mg, 3.562 mmol, 1.5 equiv), and 2-nitrobenzenesulfonyl chloride (5e, 631.6 mg, 
2.850 mmol, 1.2 equiv).  After workup, the residue was purified by use of gravity column 
chromatography on silica gel (20% EtOAc in hexanes) to give the desired coumarin 6e  
(789.6 mg, 1.995 mmol) in 84% yield as light yellow:  mp (recrystallized from CH2Cl2) 
137.4−138.2 °C; 1H NMR (CDCl3, 400 MHz) δ 8.02 (d, J = 7.6 Hz, 1 H, ArH), 7.88−7.87 (m,  
2 H, 2 × ArH), 7.75−7.67 (m, 2 H, H-5 + ArH), 7.27 (dd, J = 8.8, 2.4 Hz, 1 H, H-6), 7.19 (d,  
J = 2.4 Hz, 1 H, H-8), 6.56 (s, 1 H, H-3), 4.62 (s, 2 H, CH2Cl); 13C NMR (DMSO, 100 MHz) δ 
158.97 (C=O), 153.88, 150.33, 149.77, 147.90, 137.32, 133.31, 131.84, 127.25, 125.92, 125.67, 
118.17, 116.74, 115.98, 110.70, 41.11 (CH2Cl); IR (neat) 1734 (s, C=O), 1541 (m, N=O), 1381 
(m, S=O), 996 (m), 837 (m) cm–1; HRMS (FAB) calcd for (C16H10ClNO7S):  394.9870 found 
394.9875. 
7-(Benzyloxy)-4-(chloromethyl)-2H-chromen-2-one (8a).56  The Standard Procedure 1 was 
followed by use of 4 (360.4 mg, 1.711 mmol, 1.0 equiv) in acetone (7.0 mL), K2CO3 (354.7 mg, 
2.567 mmol, 1.5 equiv), and benzyl bromide (7a, 351.2 mg, 2.053 mmol, 1.2 equiv).  After 
workup, the residue was purified by use of gravity column chromatography on silica gel (15% 
EtOAc in hexanes) to give the desired coumarin 8a (458.0 mg, 1.523 mmol) in 89% yield as 
white solids.  The spectroscopic data were found to be in accordance with literature data.56  
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4-(Chloromethyl)-7-[(4-methylbenzyl)oxy]-2H-chromen-2-one (8b).  The Standard Procedure 
1 was followed by use of 4 (350.2 mg, 1.663 mmol, 1.0 equiv) in acetone (7.0 mL), K2CO3 
(344.7 mg, 2.494 mmol, 1.5 equiv), and 4-methylbenzyl bromide (7b, 369.2 mg, 1.995 mmol, 
1.2 equiv).  After workup, the residue was purified by use of gravity column chromatography on 
silica gel (15% EtOAc in hexanes) to give the desired coumarin 8b (471.0 mg, 1.496 mmol) in 
90% yield as white solids:  mp (recrystallized from CH2Cl2) 209.4−210.2 °C; 1H NMR (CDCl3, 
400 MHz) δ 7.53 (d, J = 8.6 Hz, 1 H, H-5), 7.30 (d, J = 7.2 Hz, 2 H, 2 × ArH), 7.19 (d, J = 7.2 
Hz, 2 H, 2 × ArH), 6.93 (d, J = 8.6 Hz, 1 H, H-6), 6.88 (s, 1 H, H-8), 6.37 (s, 1 H, H-3), 5.07  
(s, 2 H, OCH2), 4.58 (s, 2 H, CH2Cl), 2.34 (s, 3 H, CH3); 13C NMR (CDCl3, 100 MHz) δ 162.02 
(C=O), 160.75, 155.55, 149.60, 138.26, 132.49, 129.39, 127.62, 125.11, 113.26, 112.54, 110.82, 
102.19, 70.45 (OCH2), 41.27 (CH2Cl), 21.16 (CH3); IR (neat) 1719 (s, C=O), 1612 (s), 1397 (m), 
1265 (m), 1148 (m), 1058 (m) cm–1; HRMS (FAB) calcd for (C18H15ClO3):  314.0710; found 
314.0716. 
7-[(4-Chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one (8c).57  The Standard 
Procedure 1 was followed by use of 4 (320.2 mg, 1.520 mmol, 1.0 equiv) in acetone (6.0 mL), 
K2CO3 (315.2 mg, 2.280 mmol, 1.5 equiv), and 4-chlorobenzyl bromide (7c, 374.8 mg, 1.824 
mmol, 1.2 equiv).  After workup, the residue was purified by use of gravity column 
chromatography on silica gel (12% EtOAc in hexane) to give the desired coumarin 8c (453.5 mg, 
1.353 mmol) in 89% yield as white solids.  The spectroscopic data were found to be in 
accordance with literature data.57 
7-[(4-Bromobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one (8d).  The Standard Procedure 
1 was followed by use of 4 (300.1 mg, 1.425 mmol, 1.0 equiv) in acetone (6.0 mL), K2CO3 
(295.4 mg, 2.137 mmol, 1.5 equiv), and 4-bromobenzyl bromide (7d, 427.3 mg, 1.710 mmol, 1.2 
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equiv).  After workup, the residue was purified by use of gravity column chromatography on 
silica gel (12% EtOAc in hexane) to give the desired coumarin 8d (476.0 mg, 1.254 mmol) in 
88% yield as white solids:  mp (recrystallized from CH2Cl2) 203.3−204.2 °C; 1H NMR (CDCl3, 
400 MHz) δ 7.56–7.49 (m, 3 H, H-5 + 2 × ArH), 7.29–7.27 (m, 2 H, 2 × ArH), 6.92 (dd, J = 6.0, 
2.4 Hz, 1 H, H-6), 6.86 (d, J = 2.4 Hz, 1 H, H-8), 6.38 (s, 1 H, H-3), 5.06 (s, 2 H, OCH2), 4.59 (s, 
2 H, CH2Cl); 13CNMR (CDCl3, 100 MHz) δ 161.66, (C=O), 160.61, 155.61, 149.52, 134.63, 
131.90, 129.10, 125.29, 122.39, 113.22, 112.87, 111.13, 102.25, 69.73 (OCH2), 41.28 (CH2Cl); 
IR (neat) 1725 (s, C=O), 1611 (s), 1386 (m), 1265 (m), 1148 (m), 1058 (m) cm–1; HRMS (FAB) 
calcd for (C17H12ClBrO3):  377.9658; found 377.9654. 
Standard Procedure 2 for the Preparation of Conjugated Compounds 10, 12, and 14–20.  
To a solution containing 2-thio-5,6-benzopyrimidine or 2- thiopyrimidine (9, 11, or 13, 1.0 
equiv) in THF or ethanol (4.0–6.0 mL) was added K2CO3 (1.5 equiv) and the suitable  
4-(chloromethyl)coumarin (4, 6, or 8, 1.2 equiv).  After the solution was stirred at 40 °C for 
3.0−4.0 h, it was cooled down to room temperature and diluted with CH2Cl2 (4.0–6.0 mL).  
Inorganic solids were filtered off and the filtrate was concentrated under reduced pressure to 
afford the residue.  It was then purified by use of gravity column chromatography on silica gel 
(various ratio of methanol to CH2Cl2) to give the desired conjugates 10, 12, and 14–20. 
2-Oxo-4-([(4-oxo-3,4-dihydroquinazolin-2-yl)thio]methyl)-2H-chromen-7-yl 
Benzenesulfonate (10a).  The Standard Procedure 2 was followed by use of 9 (40.1 mg, 0.225 
mmol, 1.0 equiv) in THF (5.0 mL), K2CO3 (46.6 mg, 0.337 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl benzenesulfonate (6a, 94.7 mg, 0.270 mmol, 1.2 equiv).  After 
the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified by use 
of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired 
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conjugated compound 10a (99.6 mg, 0.202 mmol) in 90% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 201.7−202.6 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.05−8.00 (m, 2 H, H-5 + ArH), 7.93 (d, J = 7.2 Hz, 2 H, 2 × ArH), 7.84 (t, J = 7.3 Hz, 1 H,  
H-7), 7.77−7.74 (m, 1 H, H-8), 7.70−7.66 (m, 2 H, 2 × ArH), 7.50 (d, J = 8.0 Hz, 1 H, H-5´), 
7.42 (t, J = 7.3 Hz, 1 H, H-6), 7.13−7.11 (m, 2 H, H-6´ + H-8´), 6.72 (s, 1 H, H-3´), 4.67 (s, 2 H, 
SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 161.25 (C=O), 159.09 (N=C−S), 154.14 (C=O), 
153.75, 150.73, 150.69, 149.19, 148.02, 135.39, 134.71, 133.93, 129.99, 128.33, 127.07, 126.09, 
125.95, 120.09, 118.29, 117.33, 116.00, 110.69, 29.26 (SCH2); IR (neat) 3007 (w), 1734 (s, 
C=O), 1653 (s, C=O), 1559 (m), 1457 (m), 1275 (s, S=O), 1260 (s), 764 (s) cm–1; HRMS (FAB) 
calcd for (C24H16N2O6S2): 492.0450; found 492.0450.   
2-Oxo-4-([(4-oxo-3,4-dihydroquinazolin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Methylbenzenesulfonate (10b).  The Standard Procedure 2 was followed by use of 9 (30.1 mg, 
0.169 mmol, 1.0 equiv) in THF (4.0 mL), K2CO3 (35.0 mg, 0.253 mmol, 1.5 equiv), and 4-
(chloromethyl)coumarin-7-yl 4-methylbenzenesulfonate (6b, 73.9 mg, 0.203 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 10b (75.3 mg, 0.148 mmol) in 88% yield as off white solids:  mp 
(recrystallized from methanol/CH2Cl2) 215.1−216.2 °C; 1H NMR (CDCl3, 400 MHz) δ 8.13 (d,  
J = 7.8, 1.6 Hz, 1 H, H-5), 7.73−7.66 (m, 4 H, H-7 + H-8 + 2 × ArH), 7.50 (d, J = 8.4 Hz, 1 H, 
H-5´), 7.37 (t, J = 7.8 Hz, 1 H, H-6), 7.30 (d, J = 8.0 Hz, 2 H, 2 × ArH), 7.08 (d, J = 8.4 Hz, 1 H, 
H-6´), 6.83 (s, 1 H, H-8´), 6.63 (s, 1 H, H-3´), 4.58 (s, 2 H, SCH2), 2.41 (s, 3 H, CH3); 13C NMR 
(CDCl3, 100 MHz) δ 163.33 (C=O), 159.69 (N=C−S), 154.25 (C=O), 152.22, 151.78, 149.50, 
148.55, 146.10, 135.33, 131.87, 130.08, 128.42, 126.86, 126.55, 126.35, 125.58, 119.84, 119.12, 
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117.08, 116.49, 111.23, 30.04 (SCH2), 21.76 (CH3); IR (neat) 3008 (w), 1734 (s, C=O), 1674 (s, 
C=O), 1379 (m, S=O), 1261 (s), 1179 (w), 764 (s) cm–1; HRMS (FAB) calcd for 
(C25H18N2O6S2):  506.0610; found 506.0612. 
2-Oxo-4-([(4-oxo-3,4-dihydroquinazolin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Fluorobenzenesulfonate (10c).  The Standard Procedure 2 was followed by use of 9 (50.2 mg, 
0.282 mmol, 1.0 equiv) in THF (6.0 mL), K2CO3 (58.4 mg, 0.422 mmol, 1.5 equiv), and 4-
(chloromethyl)coumarin-7-yl 4-fluorobenzenesulfonate (6c, 0.125 g, 0.338 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 10c (0.131 g, 0.256 mmol) in 91% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 252.3−253.1 °C; 1H NMR (CDCl3, 400 MHz) δ 8.08 (d,  
J = 8.0 Hz, 1 H, H-5), 7.83−7.80 (m, 2 H, 2 × ArH), 7.71 (d, J = 8.0 Hz, 1 H, H-6), 7.64 (t,  
J = 8.0 Hz, 1 H, H-7), 7.46 (d, J = 8.2 Hz, 1 H, H-5´), 7.34 (t, J = 8.0 Hz, 1 H, H-6),  7.19−7.15 
(m, 2 H, 2 × ArH), 7.01 (d, J = 8.2 Hz, 1 H, H-6´), 6.89 (s, 1 H, H-8´), 6.62 (s, 1 H, H-3´), 4.55 
(s, 2 H, SCH2); 13C NMR (CDCl3, 100 MHz) δ 167.56 (C−F), 164.99 (C=O), 161.52, 159.53 
(N=C−S), 154.91, 154.28, 151.41, 149.62, 134.96, 131.40, 131.31, 130.37, 129.87, 129.14, 
127.45, 126.53, 126.08, 125.69, 118.76, 117.04, 116.82, 116.52, 111.17, 32.01 (SCH2); IR (neat) 
2988 (w), 2322 (w), 1750 (s, C=O), 1683 (s, C=O), 1276 (s, C−F), 750 (s) cm–1; HRMS (FAB) 
calcd for (C24H15FN2O6S2):  510.0360; found 510.0365. 
2-Oxo-4-([(4-oxo-3,4-dihydroquinazolin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Nitrobenzenesulfonate (10d).  The Standard Procedure 2 was followed by use of 9 (30.1 mg, 
0.169 mmol, 1.0 equiv) in THF (4.0 mL), K2CO3 (35.0 mg, 0.253 mmol, 1.5 equiv), and 4-
(chloromethyl)coumarin-7-yl 4-nitrobenzenesulfonate (6d, 80.2 mg, 0.203 mmol, 1.2 equiv).  
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After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 10d (80.8 mg, 0.150 mmol) in 89% yield as pale yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 252.1−253.3 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.45 (d, J = 8.8 Hz, 2 H, 2 × ArH), 8.21 (d, J = 8.8 Hz, 2 H, 2 × ArH), 8.06 (d, J = 8.0 Hz, 1 H, 
H-5), 8.01 (d, J = 8.0 Hz, 1 H, H-8), 7.76 (t, J = 8.0 Hz, 1 H, H-7), 7.52 (d, J = 8.4 Hz, 1 H,  
H-5´), 7.42 (t, J = 8.0 Hz, 1 H, H-6), 7.27 (s, 1 H, H-8´), 7.19 (d, J = 8.4 Hz, 1 H, H-6´), 6.74 (s, 
1 H, H-3´), 4.68 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 161.29 (C=O), 159.03 
(N=C−S), 153.83 (C=O), 151.20, 150.59, 150.36, 149.46, 148.02, 139.10, 134.65, 130.12, 
127.24, 126.07, 125.91, 125.14, 123.34, 120.08, 118.32, 117.63, 116.21, 110.83, 29.26 (SCH2); 
IR (neat) 3005 (w), 1735 (s, C=O), 1675 (s, C=O), 1525 (w, N=O), 1275 (m, S=O), 1194 (m), 
1119 (m), 997 (m), 750 (s) cm–1; HRMS  (FAB) calcd for (C24H15N3O8S2):  537.0301; found 
537.0300. 
2-Oxo-4-([(4-oxo-3,4-dihydroquinazolin-2-yl)thio]methyl)-2H-chromen-7-yl 2-
Nitrobenzenesulfonate (10e).  The Standard Procedure 2 was followed by use of 9 (30.2 mg, 
0.169 mmol, 1.0 equiv) in THF (4.0 mL), K2CO3 (35.1 mg, 0.254 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 2-nitrobenzenesulfonate (6e, 80.4 mg, 0.203 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 10e (85.6 mg, 0.159 mmol) in 94% yield as pale yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 261.4−260.2 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.23 (d, J = 7.6 Hz, 1 H, H-5), 8.10−8.07 (m, 3 H, 3 × ArH), 8.01 (d, J = 8.0 Hz, 1 H, ArH), 
7.92−7.88 (m, 1 H, H-8), 7.75 (t, J = 7.6 Hz, 1 H, H-7), 7.51 (d, J = 8.4 Hz, 1 H, H-5´), 7.42 (t,  
  
27
J = 7.6 Hz, 1 H, H-6), 7.28 (d, J = 2.2 Hz, 1 H, H-8´), 7.23  (dd, J = 8.4, 2.2 Hz, 1 H, H-6´), 6.75 
(s, 1 H, H-3´), 4.69 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 161.27 (C=O), 159.02 
(N=C−S), 154.17 (C=O), 153.87, 150.65, 150.27, 148.02, 147.94, 137.37, 134.71, 133.34, 
131.88, 127.38, 126.09, 125.93, 125.85, 125.71, 125.46, 120.10, 118.16, 117.79, 116.25, 110.70, 
29.29 (SCH2); IR  (neat) 3007 (w), 1735 (s, C=O), 1683 (s, C=O), 1260 (m, S=O), 1193 (m), 997 
(m), 750 (s) cm–1; HRMS (FAB) calcd for (C24H15N3O8S2):  537.0301; found 537.0300. 
4-([(5-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2-oxo-2H-chromen-7-yl 
Benzenesulfonate (12a).  The Standard Procedure 2 was followed by use of 11 (35.2 mg, 0.247 
mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (51.0 mg, 0.369 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl benzenesulfonate (6a, 0.104 g, 0.297 mmol, 1.2 equiv).  After 
the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified by use 
of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired 
conjugated compound 12a (89.2 mg, 0.195 mmol) in 82% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 196.3−197.4 °C; 1H NMR (CDCl3, 400 MHz) δ 
7.83−7.81 (m, 2 H, H-6 + ArH), 7.69−7.65 (m, 2 H, 2 × ArH), 7.62 (d, J = 8.8 Hz, 1 H, H-5´), 
7.54−7.51 (m, 2 H, 2 × ArH), 7.06−7.03 (m, 1 H, H-6´), 6.86 (d, J = 1.6 Hz, 1 H, H-8´), 6.55 (s, 
1 H, H-3´), 4.44 (s, 2 H, SCH2), 1.95 (s, 3 H, CH3); 13C NMR (DMSO-d6, 100 MHz) δ 163.49 
(C=O), 159.05 (N=C−S), 157.83 (C=O), 153.70, 150.78, 150.57, 149.17, 135.35, 133.96, 129.96, 
128.31, 126.89, 119.05, 118.30, 117.26, 115.35, 110.69, 29.44 (SCH2), 12.44 (CH3); IR (neat)  
3007 (w), 1718 (s, C=O), 1654 (s, C=O), 1559 (m), 1353 (m, S=O), 1276 (s), 836 (m), 750 (s) 
cm–1; HRMS (FAB) calcd for (C21H16N2O6S2):  456.0450; found 456.0459. 
4-([(5-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2-oxo-2H-chromen-7-yl 4-
Methylbenzenesulfonate (12b).  The Standard Procedure 2 was followed by use of 11 (30.2 mg, 
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0.212 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (44.0 mg, 0.319 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 4-methylbenzenesulfonate (6b, 92.9 mg, 0.255 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 12b (79.9 mg, 0.170 mmol) in 81% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 210.1−211.2 °C; 1H NMR (CDCl3, 400 MHz) δ 
7.69−7.65 (m, 3 H, H-6 + 2 × ArH), 7.61 (d, J = 8.6 Hz, 1 H, H-5´), 7.31−7.29 (m, 2 H,  
2 × ArH), 7.06 (dd, J = 8.6, 2.2 Hz, 1 H, H-6´), 6.84 (d, J = 2.2 Hz, 1 H, H-8´), 6.54 (s, 1 H,  
H-3´), 4.44 (s, 2 H, SCH2), 2.41 (s, 3 H, CH3), 1.94 (s, 3 H, CH3); 13C NMR (CDCl3, 100 MHz) 
δ 163.96 (C=O), 159.98 (N=C−S), 155.93 (C=O), 154.08, 151.63, 151.43, 149.59, 146.13, 
131.64, 130.02, 128.32, 125.45, 120.95, 118.99, 117.01, 115.94, 111.15, 29.84 (SCH2), 21.64 
(CH3), 12.57 (CH3); IR  (neat) 3005 (w), 1718 (s, C=O), 1653 (s, C=O), 1558 (m), 1353 (m, 
S=O), 1260 (s), 836 (m), 764 (s) cm–1; HRMS (FAB) calcd for (C22H18N2O6S2):  470.0606; 
found 470.0600. 
4-([(5-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2-oxo-2H-chromen-7-yl 4-
Fluorobenzenesulfonate (12c).  The Standard Procedure 2 was followed by use of 11 (50.1 mg, 
0.352 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (73.0 mg, 0.528 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 4-fluorobenzenesulfonate (6c, 0.156 g, 0.423 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 12c (0.129 g, 0.271 mmol) in 83% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 249.3−250.1 °C; 1H NMR (CDCl3, 400 MHz) δ 
7.84−7.80 (m, 2 H, 2 × ArH), 7.62−7.60 (m, 2 H, H-6 + H-5´), 7.20−7.16 (m, 2 H, 2 × ArH), 
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6.99 (dd, J = 8.8, 2.2 Hz, 1 H, H-6´), 6.89 (d, J = 2.2 Hz, 1 H, H-8´), 6.53 (s, 1 H, H-3´), 4.42  
(s, 2 H, SCH2), 1.91 (s, 3 H, CH3); 13C NMR (DMSO-d6, 100 MHz) δ 167.03  (C−F), 164.49 
(C=O), 163.57 (N=C−S), 159.03, 157.93, 153.77, 150.71, 150.53, 131.75, 131.65, 130.28, 
126.86, 118.98, 118.27, 117.38, 117.32, 117.23, 115.41, 110.72, 29.44 (SCH2), 12.36 (CH3); IR 
(neat) 3004 (w), 1717 (s, C=O), 1540 (w), 1367 (w, S=O), 1276 (m, C−F), 988 (w), 764 (s) cm–1; 
HRMS (FAB) calcd for (C21H15FN2O6S2):  474.0356; found 474.0350. 
4-([(5-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2-oxo-2H-chromen-7-yl 4-
Nitrobenzenesulfonate (12d).  The Standard Procedure 2 was followed by use of 11 (30.2 mg, 
0.212 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (44.0 mg, 0.319 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 4-nitrobenzenesulfonate (6d, 0.101 g, 0.255 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 12d (81.9 mg, 0.164 mmol) in 81% yield as light yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 251.5−252.4 °C; 1H NMR (CDCl3, 400 MHz) δ 8.40 
(d, J = 8.8 Hz, 2 H, 2 × ArH), 8.08 (d, J = 8.8 Hz, 2 H, 2 × ArH), 7.73 (s, 1 H, H-6), 7.66 (d,  
J = 8.8 Hz, 1 H, H-5´), 7.04 (dd, J = 8.8, 2.2 Hz, 1 H, H-6´), 6.98 (d, J = 2.2 Hz, 1 H, H-8´), 6.61 
(s, 1 H, H-3´), 4.48 (s, 2 H, SCH2), 2.00 (s, 3 H, CH3); 13C NMR (CDCl3, 100 MHz) δ 165.02 
(C=O), 159.34 (N=C−S), 155.87, 154.34, 151.69, 151.23, 150.98, 149.04, 140.44, 129.85, 
125.86, 124.66, 121.07, 118.42, 117.55, 116.67, 111.12, 29.95 (SCH2), 12.68 (CH3); IR (neat) 
3006 (w), 1717 (s, C=O), 1540 (w, N=O), 1472 (w), 1260 (m, S=O), 1183 (w), 988 (w), 750 (s) 
cm–1; HRMS (FAB) calcd for (C21H15N3O8S2):  501.0301; found 501.0305. 
4-([(5-Methyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2-oxo-2H-chromen-7-yl 2-
Nitrobenzenesulfonate (12e).  The Standard Procedure 2 was followed by use of 11 (25.1 mg, 
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0.176 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (36.6 mg, 0.265 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 2-nitrobenzenesulfonate (6e, 83.8 mg, 0.212 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 12e (70.0 mg, 0.138 mmol) in 84% yield as light yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 259.4−260.1 °C; 1H NMR (CDCl3, 400 MHz) δ 8.00 
(d, J = 8.0 Hz, 1 H, ArH), 7.87−7.86 (m, 2 H, 2 × ArH), 7.74−7.68 (m, 3 H, H-6 + H-5´ + ArH), 
7.25−7.22 (m, 1 H, H-6´), 7.14 (d, J = 2.0 Hz, 1 H, H-8´), 6.60 (s, 1 H, H-3´), 4.49 (s, 2 H, 
SCH2), 1.99 (s, 3 H, CH3); 13C NMR (CDCl3, 100 MHz) δ 164.05 (C=O), 159.81, 156.02, 
154.14, 150.81, 150.19, 149.59, 135.87, 132.14, 131.94, 127.76, 125.78, 125.02, 120.83, 118.67, 
117.50, 116.20, 111.16, 31.76 (SCH2), 12.53 (CH3); IR (neat) 3006 (w), 1717 (s, C=O), 1653 (s, 
C=O), 1559 (w, N=O), 1276 (s, S=O), 850 (w), 750 (s) cm–1; HRMS (FAB) calcd for 
(C21H15N3O8S2):  501.0301; found 501.0300. 
2-Oxo-4-([(6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2H-chromen-7-yl 
Benzenesulfonate (14a).  The Standard Procedure 2 was followed by use of 13 (30.1 mg, 0.235 
mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (48.7 mg, 0.352 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl benzenesulfonate (6a, 98.8 mg, 0.282 mmol, 1.2 equiv).    After 
the reaction mixture was stirred at 40 °C for 3.0 h, then workup, the residue was purified by use 
of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired 
conjugated compound 14a (88.2 mg, 0.199 mmol) in 85% yield as white solids:  mp 
(recrystallized from dichloromethane/methanol) 187.4−188.3 °C; 1H NMR (CDCl3, 400 MHz) δ 
7.85−7.82 (m, 3 H, H-6 + 2 × ArH), 7.70−7.66 (m, 1 H, ArH), 7.60 (d, J = 8.0 Hz, 1 H, H-5´), 
7.59-7.51 (m, 2 H, 2 × ArH), 7.04 (d, J = 8.0 Hz, 1 H, H-6´), 6.86 (s, 1 H, H-8´), 6.58 (s, 1 H,  
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H-3´), 6.23−6.21 (m, 1 H, H-5), 4.48 (s, 2 H, SCH2); 13C NMR (CDCl3, 100 MHz) δ 164.91 
(C=O), 159.61 (N=C−S), 154.88 (C=O), 154.14, 151.59, 148.93, 134.78, 129.45, 129.19, 128.34, 
128.24, 125.44, 118.94, 116.99, 116.28, 111.55, 111.23, 29.99 (SCH2); IR (neat), 3006 (w), 1718 
(s, C=O), 1653 (s, C=O), 1558 (m), 1353 (m, S=O), 1276 (s), 836 (m), 750 (s) cm–1; HRMS 
(FAB) calcd for (C20H14N2O6S2):  442.0293; found 442.0290. 
2-Oxo-4-([(6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Methylbenzenesulfonate (14b).   The Standard Procedure 2 was followed by use of 13 (30.2 
mg, 0.236 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (48.8 mg, 0.353 mmol, 1.5 equiv), and 
4-(chloromethyl)coumarin-7-yl 4-methylbenzenesulfonate (6b, 0.103 g, 0.283 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 3.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 14b (91.4 mg, 0.200 mmol) in 85% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 191.4−192.5 °C; 1H NMR (CDCl3, 400 MHz) δ 7.85 (d,  
J = 6.8 Hz, 1 H, H-6), 7.71 (d, J = 8.2 Hz, 2 H, 2 × ArH), 7.60 (d, J =8.8 Hz, 1 H, H-5´), 7.31 (d, 
J = 8.2 Hz, 2 H, 2 × ArH), 7.06 (dd, J = 8.8, 2.0 Hz, 1 H, H-6´), 6.85 (d, J = 2.0 Hz, 1 H, H-8´), 
6.58, (s, 1 H, H-3´), 6.23 (d, J = 6.8 Hz, 1 H, H-5), 4.49 (s, 2 H, SCH2), 2.43 (s, 3 H, CH3); 13C 
NMR (CDCl3, 100 MHz) δ 164.80 (C=O), 159.68 (C=O), 159.61 (N=C−S), 154.76, 154.15, 
151.75, 148.98, 146.08, 131.84, 130.05, 128.36, 125.41, 118.96, 116.92, 116.22, 111.52, 111.18, 
30.03 (SCH2), 21.70 (CH3); IR (neat) 3007 (w), 1717 (s, C=O), 1653 (s, C=O), 1558 (m), 1353 
(m, S=O), 1276 (s), 1183 (w), 996 (m), 764 (s) cm–1 ; HRMS (FAB) calcd for (C21H16N2O6S2):  
456.0450; found 456.0454. 
2-Oxo-4-([(6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Fluorobenzenesulfonate (14c).  The Standard Procedure 2 was followed by use of 13 (40.2 mg, 
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0.314 mmol, 1.0 equiv) in ethanol (5.0 mL), K2CO3 (65.0 mg, 0.471 mmol, 1.5 equiv), and 4-
(chloromethyl)coumarin-7-yl 4-fluorobenzenesulfonate (6c, 0.139 g, 0.376 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 3.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 14c (125.4 mg, 0.272 mmol) in 88% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 243.3−244.1 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.02−7.94 (m, 4 H, H-6 + H-5´ + 2 × ArH), 7.55−7.51 (m, 2 H, 2 × ArH), 7.20 (d, J = 2.0 Hz,  
1 H, H-8´), 7.11 (dd, J = 8.8, 2.0 Hz, 1 H, H-6´), 6.61 (s, 1 H, H-3´), 6.18 (d, J = 5.6 Hz, 1 H,  
H-5), 4.58 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 167.49 (C−F), 164.92 (C=O), 
163.86, 159.86 (N=C−S), 154.29, 154.07, 151.34, 149.36, 141.07, 131.31, 131.21, 130.63, 
125.55, 118.73, 117.14, 116.98, 116.76, 116.12, 111.16, 29.90 (SCH2); IR (neat) 3007 (w), 1717 
(s, C=O), 1367 (w, S=O), 1276 (m, C−F), 1183 (w), 989 (m), 750 (s) cm–1; HRMS (FAB) calcd 
for (C20H13FN2O6S2):  460.0200; found 460.0200 
2-Oxo-4-([(6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2H-chromen-7-yl 4-
Nitrobenzenesulfonate (14d).  The Standard Procedure 2 was followed by use of 13 (40.1 mg, 
0.313 mmol, 1.0 equiv) in ethanol (6.0 mL), K2CO3 (64.9 mg, 0.469 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 4-nitrobenzenesulfonate (6d, 0.149 g, 0.375 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 3.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 14d (0.130 g, 0.266 mmol) in 85% yield as pale yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 246.5−247.4 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.45 (d, J = 8.6 Hz, 2 H, 2 × ArH), 8.21 (d, J = 8.6 Hz, 2 H, 2 × ArH), 7.98−7.95 (m, 2 H,  
H-6 + H-5´), 7.27 (s, 1 H, H-8´), 7.17 (d, J = 8.8 Hz, 1 H, H-6´), 6.62 (s, 1 H, H-3´), 6.18 (br,  
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1 H, H-5), 4.58 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 164.04 (C=O), 162.42 (C=O), 
158.99 (N=C−S), 154.50, 153.81, 150.50, 150.30, 147.93, 137.34, 131.89, 127.21, 125.70, 
118.17, 117.73, 115.63, 110.71, 109.23, 29.62 (SCH2); IR (neat) 3007 (w), 1717 (s, C=O), 1559 
(w, N=O), 1378 (w, S=O), 1276 (m), 849 (m), 750 (s) cm–1;  HRMS (FAB) calcd for 
(C20H13N3O8S2):  487.0144; found 487.0140. 
2-Oxo-4-([(6-oxo-1,6-dihydropyrimidin-2-yl)thio]methyl)-2H-chromen-7-yl 2-
Nitrobenzenesulfonate (14e).  The Standard Procedure 2 was followed by use of 13 (30.1 mg, 
0.235 mmol, 1.0 equiv) in ethanol (4.0 mL), K2CO3 (48.7 mg, 0.352 mmol, 1.5 equiv), and  
4-(chloromethyl)coumarin-7-yl 2-nitrobenzenesulfonate (6e, 0.112 g, 0.282 mmol, 1.2 equiv).  
After the reaction mixture was stirred at 40 °C for 3.0 h, then workup, the residue was purified 
by use of gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the 
desired conjugated compound 14e (99.5 mg, 0.204 mmol) in 87% yield as pale yellow solids:  
mp (recrystallized from methanol/CH2Cl2) 256.4−257.1 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
8.23 (d, J = 8.0 Hz, 1 H, ArH), 8.11−8.07 (m, 2 H, 2 × ArH), 8.00 (d, J = 8.8 Hz, 1 H, H-5´), 
7.93−7.89 (m, 2 H, H-6 + ArH), 7.30 (d, J = 2.4 Hz, 1 H, H-8´), 7.21 (dd, J = 8.8, 2.4 Hz, 1 H, 
H-6´), 6.63 (s, 1 H, H-3´), 6.17 (d, J = 5.2 Hz, 1 H, H-5), 4.58 (s, 2 H, SCH2); 13C NMR 
(DMSO-d6, 100 MHz) δ 164.73 (C=O), 163.10 (C=O), 159.68, 155.21, 154.49, 151.18, 150.98, 
148.61, 138.03, 134.00, 132.57, 127.90, 126.60, 126.38, 118.86, 118.41, 116.31, 111.39, 109.92, 
30.30 (SCH2); IR (neat) 3008 (w), 1717 (s, C=O), 1653 (s, C=O), 1559 (m, N=O), 1276 (s, 
S=O), 841 (w), 750 (s) cm–1; HRMS (FAB) calcd for (C20H13N3O8S2):  487.0144; found 
487.0140. 
2-([(7-(Benzyloxy)-2-oxo-2H-chromen-4-yl)methyl]thio)quinazolin-4(3H)-one (15a).  The 
Standard Procedure 2 was followed by use of 9 (30.1 mg, 0.169 mmol, 1.0 equiv) in THF (4.0 
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mL), K2CO3 (35.0 mg, 0.253 mmol, 1.5 equiv), and 7-benzyloxy-4-(chloromethyl)coumarin (8a, 
60.9 mg, 0.203 mmol, 1.2 equiv).  After the reaction mixture was stirred at 40 °C for 4.0 h, then 
workup, the residue was purified by use of gravity column chromatography on silica gel (2.0% 
methanol in CH2Cl2) to give the desired conjugated compound 15a (59.0 mg, 0.133 mmol) in 
82% yield as white solids:  mp (recrystallized from methanol/CH2Cl2) 235.5−236.3 °C; 1H NMR 
(DMSO-d6, 400 MHz) δ 7.92 (d, J = 8.8 Hz, 1 H, H-5), 7.86 (d, J = 7.2 Hz, 1 H, H-5´), 
7.46−7.45 (m, 2 H, H-7 + H-8), 7.41−7.37 (m, 3 H, H-6 + 2 × ArH), 7.35−7.33 (m, 1 H, ArH), 
7.21 (d, J = 8.4 Hz, 1 H, ArH), 7.06−7.00 (m, 3 H, H-6´ + H-8´ + ArH), 6.45 (s, 1 H, H−3´), 5.74 
(s, 1 H, NH), 5.21 (s, 2 H, OCH2), 4.52 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 
169.98 (C=O), 165.63 (C=O), 161.41 (N=C−S), 160.38, 155.14, 154.37, 151.56, 136.36, 131.14, 
128.60, 128.16, 127.91, 126.80, 126.16, 124.33, 122.03, 121.23, 112.72, 112.14, 111.32, 102.02, 
69.94 (OCH2), 29.66 (SCH2); IR (neat) 3005 (w), 1734 (s, C=O), 1684 (s, C=O), 1558 (m), 1276 
(s), 750 (s) cm–1; HRMS (FAB) calcd for (C25H18N2O4S):  442.0990; found 442.0997. 
2-([(7-[(4-Methylbenzyl)oxy]-2-oxo-2H-chromen-4-yl)methyl]thio)quinazolin-4(3H)-one 
(15b).  The Standard Procedure 2 was followed by use of 9 (40.1 mg, 0.225 mmol, 1.0 equiv) in 
THF (4.0 mL), K2CO3 (46.6 mg, 0.337 mmol, 1.5 equiv), and 4-(chloromethyl)-7-[(4-
methylbenzyl)oxy]coumarin (8b, 85.0 mg, 0.270 mmol, 1.2 equiv).  After the reaction mixture 
was stirred at 40 °C for 4.0 h, then workup, the residue was purified by use of gravity column 
chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired conjugated 
compound 15b (83.0 mg, 0.182 mmol) in 86% yield as white solids:  mp (recrystallized from 
methanol/CH2Cl2) 260.5−261.4 °C; 1H NMR (DMSO-d6, 400 MHz) δ 8.02 (d, J = 8.0 Hz, 1 H, 
H-5), 7.90 (d, J = 8.8 Hz, 1 H, H-5´), 7.78−7.74 (m, 1 H, H-7), 7.54 (d, J = 8.4 Hz, 1 H, H-8), 
7.42 (t, J = 8.0 Hz, 1 H, H-6), 7.34 (d, J = 8.0 Hz, 2 H, 2 × ArH), 7.19 (d, J = 8.0 Hz, 2 H,  
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2 × ArH), 7.07−7.04 (m, 2 H, H-6´ + H-8´), 6.51 (s, 1 H, H−3´), 5.17 (s, 2 H, OCH2), 4.67 (s,  
2 H, SCH2), 2.29 (s, 3 H, CH3); 13C NMR (DMSO-d6, 100 MHz) δ 169.98, 165.63, 161.56 
(C=O), 160.05 (N=C−S), 155.13, 154.37, 151.67, 136.36, 131.14, 128.60, 128.16, 127.99, 
126.80, 126.14, 124.40, 122.03, 121.23, 112.92, 112.14, 111.32, 102.05, 69.85 (OCH2), 29.34 
(SCH2), 20.78 (CH3); IR (neat) 3001 (w), 2989 (w), 1717 (s, C=O), 1674 (s, C=O), 1559 (m), 
1457 (m), 1260 (s), 764 (s) cm–1;  HRMS (FAB) calcd for (C26H20N2O4S):  456.1144; found 
456.1140. 
2-([(7-(Benzyloxy)-2-oxo-2H-chromen-4-yl)methyl]thio)-5-methylpyrimidin-4(3H)-one 
(16a).  The Standard Procedure 2 was followed by use of 11 (40.4 mg, 0.284 mmol, 1.0 equiv) in 
ethanol (5.0 mL), K2CO3 (58.9 mg, 0.426 mmol, 1.5 equiv), and 7-benzyloxy-4-
(chloromethyl)coumarin (8a, 0.102 g, 0.341 mmol, 1.2 equiv).  After the reaction mixture was 
stirred at 40 °C for 4.0 h, then workup, the residue was purified by use of gravity column 
chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired conjugated 
compound 16a (95.7 mg, 0.236 mmol) in 83% yield as white solids:  mp (recrystallized from 
methanol/CH2Cl2) 230.5−231.3 °C; 1H NMR (DMSO-d6, 400 MHz) δ 7.82−7.80 (m, 2 H, H-6 + 
H-5´), 7.47−7.31 (m, 5 H, 5 × ArH), 7.09 (d, J = 2.8 Hz, 1 H, H-8´), 7.05 (d, J = 8.4 Hz, 1 H,  
H-6´), 6.39 (s, 1 H, H-3´), 5.22 (s, 2 H, OCH2), 4.56 (s, 2 H, SCH2), 1.86 (s, 3 H, CH3); 13C 
NMR (DMSO-d6, 100 MHz) δ 164.25, 161.54 (C=O), 160.00, 158.68, 155.04, 151.60, 150.66, 
136.24, 128.55, 128.13, 127.87, 127.36, 119.72, 112.91, 111.78, 111.61, 102.06, 69.93 (OCH2), 
29.46 (SCH2), 12.47 (CH3); IR (neat) 3005 (w), 1702 (s, C=O), 1609 (s, C=O), 1456 (m), 1331 
(m), 1275 (s), 1138 (m), 750 (s) cm–1; HRMS (FAB) calcd for (C22H18N2O4S):  406.0990; found 
406.0990. 
5-Methyl-2-([(7-[(4-methylbenzyl)oxy]-2-oxo-2H-chromen-4-yl)methyl]thio) pyrimidin-
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4(3H)-one (16b).   The Standard Procedure 2 was followed by use of 11 (40.2 mg, 0.283 mmol, 
1.0 equiv) in ethanol (5.0 mL), K2CO3 (58.6 mg, 0.424 mmol, 1.5 equiv), and 4-(chloromethyl)-
7-[(4-methylbenzyl)oxy]coumarin (8b, 0.107 g, 0.339 mmol, 1.2 equiv).  After the reaction 
mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified by use of gravity 
column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired conjugated 
compound 16b (0.104 g, 0.229 mmol) in 81% yield as white solids:  mp (recrystallized from 
methanol/CH2Cl2) 230.1−231.3 °C; 1H NMR (DMSO-d6, 400 MHz) δ 7.82−7.80 (m, 2 H, H-6 + 
H-5´), 7.34 (d, J = 7.6 Hz, 2 H, 2 × ArH), 7.20 (d, J = 7.6 Hz, 2 H, 2 × ArH), 7.07 (s, 1 H, H-8´), 
7.04 (d, J = 8.8 Hz, 1 H, H-6´), 6.39 (s, 1 H, H-3´), 5.17 (s, 2 H, OCH2), 4.55 (s, 2 H, SCH2), 
2.29 (s, 3 H, CH3), 1.86 (s, 3 H, CH3); 13C NMR (Pyridine-d5, 100 MHz) δ 165.12 (C=O), 
162.32 (N=C−S), 160.76 (C=O), 159.62, 156.13, 152.05, 151.49, 138.20, 133.76, 129.66, 
128.30, 126.32, 119.32, 113.26, 113.06, 112.51, 102.47, 70.63 (OCH2), 30.49 (SCH2), 21.04 
(CH3), 13.01 (CH3); IR (neat) 3006 (w), 1717 (m, C=O), 1671 (m, C=O), 1558 (m), 1275 (s), 
750 (s) cm–1; HRMS (FAB) calcd for (C23H20N2O4S):  456.1144; found 456.1140. 
2-([(7-[(4-Chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)methyl]thio)-5-methyl pyrimidin-
4(3H)-one (16c).  The Standard Procedure 2 was followed by use of 11 (30.3 mg, 0.213 mmol, 
1.0 equiv) in ethanol (4.0 mL), K2CO3 (44.2 mg, 0.320 mmol, 1.5 equiv), and 7-[(4-
chlorobenzyl)oxy]-4-(chloromethyl)coumarin 8c, 85.7 mg, 0.256 mmol, 1.2 equiv).  After the 
reaction mixture was stirred at 40 °C for 4.0 h, then workup, the residue was purified by use of 
gravity column chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired 
conjugated compound 16c (76.9 mg, 0.175 mmol) in 82% yield as white solids:  mp 
(recrystallized from methanol/CH2Cl2) 252.1−253.5 °C; 1H NMR (DMSO-d6, 400 MHz)  
δ 7.82−7.80 (m, 2 H, H-6 + H-5´), 7.50−7.44 (m, 4 H, 4 × ArH), 7.08 (d, J = 2.6 Hz, 1 H, H-8´), 
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7.04 (dd, J = 9.2, 2.6 Hz, 1 H, H-6´), 6.39 (s, 1 H, H-3´), 5.22 (s, 2 H, OCH2), 4.56 (s, 2 H, 
SCH2), 1.86 (s, 3 H, CH3); 13C NMR (DMSO-d6, 100 MHz) δ 163.40 (C=O), 161.29, 159.94, 
157.94, 155.02, 151.49, 150.89, 135.27, 132.71, 129.64, 128.52, 126.35, 119.06, 112.82, 111.88, 
111.69, 102.04, 69.01 (OCH2), 29.43 (SCH2), 12.44 (CH3); IR (neat) 3007 (w), 1700 (s, C=O), 
1653 (s, C=O), 1559 (m), 1457 (m), 1275 (s), 750 (s) cm–1; HRMS (FAB) calcd for 
(C22H17ClN2O4S):  440.0600; found 440.0601.  
2-([(7-(Benzyloxy)-2-oxo-2H-chromen-4-yl)methyl]thio)pyrimidin-4(3H)-one (17a).  The 
Standard Procedure 2 was followed by use of 13 (20.2 mg, 0.158 mmol, 1.0 equiv) in ethanol 
(4.0 mL), K2CO3 (32.7 mg, 0.236 mmol, 1.5 equiv), and 7-benzyloxy-4-(chloromethyl)coumarin 
(8a, 56.9 mg, 0.189 mmol, 1.2 equiv).  After the reaction mixture was stirred at 40 °C for 4.0 h, 
then workup, the residue was purified by use of gravity column chromatography on silica gel 
(2.0% methanol in CH2Cl2) to give the desired conjugated compound 17a (54.4 mg, 0.139 mmol) 
in 88% yield as light yellow solids:  mp (recrystallized from methanol/CH2Cl2) 220−225 °C; 1H 
NMR (DMSO-d6, 400 MHz) δ 7.95 (br, 1 H, H-6), 7.82 (d, J = 8.8 Hz, 1 H, H-5´), 7.47−7.32 
(m, 5 H, 5 × ArH), 7.10−7.09 (m, 1 H, H-8´), 7.07−7.04 (m, 1 H, H-6´), 6.42, (s, 1 H, H-3´), 6.19 
(br, 1 H, H-5), 5.23 (s, 2 H, OCH2), 4.58 (s, 2 H, SCH2);  13C NMR (DMSO-d6, 100 MHz) δ 
163.92 (C=O), 162.46 (C=O), 161.49, 159.95 (N=C−S), 155.03, 154.43, 151.43, 136.21, 128.50, 
128.08, 127.84, 126.30, 112.83, 111.82, 111.59, 109.32, 101.99, 69.89 (OCH2), 29.62 (SCH2); 
IR (neat) 3008 (m), 1699 (s, C=O), 1684 (s, C=O), 1559 (m), 1276 (s), 750 (s) cm–1; HRMS 
(FAB) calcd for (C21H16N2O4S):  392.0831; found 392.0836. 
2-([(7-[(4-Bromobenzyl)oxy]-2-oxo-2H-chromen-4-yl)methyl]thio)pyrimidin-4(3H)-one 
(17d).  The Standard Procedure 2 was followed by use of 13 (30.5 mg, 0.238 mmol, 1.0 equiv) in 
ethanol (4.0 mL), K2CO3 (49.3 mg, 0.357 mmol, 1.5 equiv), and 7-[(4-bromobenzyl)oxy]-4-
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(chloromethyl)coumarin (8d, 0.108 g, 0.286 mmol, 1.2 equiv).  After the reaction mixture was 
stirred at 40 °C for 4.0 h, then workup, the residue was purified by use of gravity column 
chromatography on silica gel (2.0% methanol in CH2Cl2) to give the desired conjugated 
compound 17d (99.5 mg, 0.212 mmol) in 89% yield as white solids:  mp (recrystallized from 
methanol/CH2Cl2) 250.4−251.3 °C; 1H NMR (DMSO-d6, 400 MHz) δ 7.84 (d, J = 7.2 Hz, 1 H, 
H-6), 7.58 (d, J = 8.4 Hz, 2 H, 2 × ArH), 7.45−7.41 (m, 3 H, H-5´ + 2 × ArH), 7.05 (d, J = 2.4 
Hz, 1 H, H-8´), 7.01 (dd, J = 8.8, 2.4 Hz, 1 H, H-6´), 6.39 (s, 1 H, H-3´), 5.50 (d, J = 7.2 Hz, 1 H, 
H-5), 5.20 (s, 2 H, OCH2), 4.40 (s, 2 H, SCH2); 13C NMR  (DMSO-d6, 100 MHz) δ 172.10 
(C=O), 166.45 (N=C−S), 161.10 (C=O), 160.24, 155.01, 154.19, 152.88, 135.80, 131.47, 129.99, 
126.67, 121.23, 112.63, 112.16, 111.09, 108.44, 101.97, 69.00 (OCH2), 29.48 (SCH2); IR (neat) 
3006 (w), 1702 (s, C=O), 1609 (s, C=O), 1331 (m), 1275 (s), 1138 (m), 750 (s) cm–1; HRMS 
(FAB) calcd for (C21H15BrN2O4S):  469.9930; found 469.9930. 
2-([(7-Hydroxy-2-oxo-2H-chromen-4-yl)methyl]thio)quinazolin-4(3H)-one (18).  The 
Standard Procedure 2 was followed by use of 9 (50.1 mg, 0.281 mmol, 1.0 equiv) in THF (4.0 
mL), K2CO3 (58.3 mg, 0.423 mmol, 1.5 equiv), and 4-(chloromethyl)-7-hydroxycoumarin (4, 
71.0 mg, 0.337 mmol, 1.2 equiv).  After the reaction mixture was stirred at 40 °C for 4.0 h and 
then workup, the residue was purified by use of gravity column chromatography on silica gel 
(2.0% methanol in CH2Cl2) to give the conjugated compound 18 (88.2 mg, 0.250 mmol) in 89% 
yield as white solids: mp (recrystallized from methanol/CH2Cl) 257.2−259.6 °C; 1H NMR 
(DMSO-d6, 400 MHz) δ 8.01 (d, J = 7.6 Hz, 1 H, H-5), 7.80−7.73 (m, 2 H, H-5´ + H-7), 7.53 
(d, J = 8.4 Hz, 1 H, H-8), 7.41 (t, J = 7.2 Hz, 1 H, H-6), 6.82 (d, J = 8.8 Hz, 1 H, H-6´), 6.72 (s, 1 
H, H-8´), 6.43 (s, 1 H, H-3´), 4.64 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 100 MHz) δ 161.39 
(C=O), 161.21 (N=C−S), 160.16 (C=O), 155.26, 154.25, 151.75, 148.09, 134.71, 126.60, 126.58, 
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126.11, 125.93, 120.07, 113.04, 111.32, 110.35, 102.54, 29.31 (SCH2); IR (neat) 3008 (w), 1708 
(m, C=O), 1588 (m), 1458 (m), 1260 (m), 750 (s) cm–1; HRMS (FAB) calcd for (C18H12N2O4S): 
352.0520; found 352.0522. 
2-([(7-Hydroxy-2-oxo-2H-chromen-4-yl)methyl]thio)-5-methylpyrimidin-4(3H)-one (19).  
The Standard Procedure 2 was followed by use of 11 (40.2 mg, 0.283 mmol, 1.0 equiv) in 
ethanol (5.0 mL), K2CO3 (58.6 mg, 0.424 mmol, 1.5 equiv), and 4-(chloromethyl)-7-
hydroxycoumarin (4, 71.4 mg, 0.339 mmol, 1.2 equiv).  After the reaction mixture was stirred at 
40 °C for 4.0 h, then workup, the residue was purified by use of gravity column chromatography 
on silica gel (2.0% methanol in CH2Cl2) to give the conjugated compound 19 (74.2 mg, 0.235 
mmol) in 83% yield as white solids:  mp (recrystallized from methanol/CH2Cl2) 240.4−242.2 °C; 
1H NMR (DMSO-d6, 400 MHz) δ 7.47–7.45 (m, 2 H, H-6 + H-5´), 6.62 (dd, J = 8.6, 1.6 Hz, 1 H, 
H-6´), 6.56 (d, J = 1.6 Hz, 1 H, H-8´), 6.10 (s, 1 H, H-3´), 4.31 (s, 2 H, SCH2), 1.76 (s, 3 H, 
CH3); 13C NMR (DMSO-d6, 100 MHz) δ 172.47 (C=O), 164.42 (N=C−S), 164.21 (C=O), 
160.76, 155.38, 154.12, 151.36, 125.87, 115.14, 113.92, 109.01, 108.09, 102.47, 29.62 (SCH2), 
13.96 (CH3); IR (neat) 3008 (w), 1708 (s, C=O), 1588 (m), 1458 (m), 1276 (m), 750 (s) cm–1; 
HRMS (FAB) calcd for (C15H12N2O4S):  316.0518; found 316.0516. 
2-([(7-Hydroxy-2-oxo-2H-chromen-4-yl)methyl]thio)pyrimidin-4(3H)-one (20).  The 
Standard Procedure 2 was followed by use of 13 (40.1 mg, 0.313 mmol, 1.0 equiv) in ethanol 
(4.0 mL), K2CO3 (64.9 mg, 0.469 mmol, 1.5 equiv), and 4-(chloromethyl)-7-hydroxycoumarin 
(4, 79.1 mg, 0.375 mmol, 1.2 equiv).  After the reaction mixture was stirred at 40 °C for 4.0 h, 
then workup, the residue was purified by use of gravity column chromatography on silica gel 
(2.0% methanol in CH2Cl2) to give the conjugated compound 20 (75.4 mg, 0.250 mmol) in 81% 
yield as yellow solids:  mp (recrystallized from methanol/CH2Cl2) 223.3−225.2 °C; 1H NMR 
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(DMSO-d6, 400 MHz) δ 7.57−7.53 (m, 2 H, H-6 + H-5´), 6.71−6.67 (m, 2 H, H-6´ + H-8´), 
6.21 (s, 1 H, H-3´), 5.65 (d, J = 5.6 Hz, 1 H, H-5), 4.35 (s, 2 H, SCH2); 13C NMR (DMSO-d6, 
100 MHz) δ 172.04 (C=O), 166.53 (N=C−S), 162.68 (C=O), 160.47, 155.14, 153.84, 153.74, 
126.04, 113.29, 109.80, 109.10, 107.67, 102.39, 29.49 (SCH2); IR (neat) 2989 (w), 1708 (s, 
C=O), 1588 (m), 1276 (m), 750 (s) cm–1; HRMS (FAB) calcd for (C14H10N2O4S):  302.0361; 
found 302.0364. 
ASSOCIATED CONTENT 
Supporting Information.  This material is available free of charge via the Internet at 
http://pubs.acs.org.”  
AUTHOR INFORMATION 
Corresponding Author 
*Correspondence and request for the materials should be addressed to Jih Ru Hwu 
(jrhwu@mx.nthu.edu.tw), Shwu-Chen Tsay (tsay.susan@gmail.com), or Johan Neyts 
(johan.neyts@rega.kuleuven.be). 
Author Contributions 
The manuscript was written through contributions of all authors.  All authors have given 
approval to the final version of the manuscript.  
ACKNOWLEDGMENT 
For financial support, we thank the National Science Council (grant No. NSC 102-2633-M-007-
001), Ministry of Education of R.O.C. (grant No. 102N2011E1 and 102N2018E1), and National 
Central University (grant No. 102G918).  The work in Leuven is supported by the European 
  
41
Commission SILVER project within the 7th Framework Programme as Cooperation Project 
Grant Agreement (No. 260644).   
ABBREVIATIONS 
ADP, adenosine diphosphate; CHIK, chikungunya; CHIKV, Chikungunya virus; CC50, cytotoxic 
concentration; DNA, deoxyribonucleic acid; EC50, half maximal effective concentration; HBV, 
hepatitis B virus; HCV, hepatitis C virus; RNA, ribonucleic acid; HIV, human 
immunodeficiency virus; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium; PARP, poly ADP ribose polymerase; RT–PCR, reverse 
transcription polymerase chain reaction; SAR, structure–activity relationship; SI, selectivity 
index; TLC, thin layer chromatography. 
References 
   (1)  Schwartz, O.; Albert, M. L. Biology and Pathogenesis of Chikungunya Virus. Nat. Rev. 
2012, 8, 491–500.  
  (2) Gerardin, P.; Barau, G.; Michault, A.; Bintner, M.; Randrianaivo, H.; Choker, G.; 
Lenglet, Y.; Touret, Y.; Bouveret, A.; Grivard, P.; Roux, K. L.; Blanc, S.; Schuffenecker, I.; 
Couderc, T.; Arenzana-Seisdedos, F.; Lecuit, M.; Robillard, P. Y. Multidisciplinary Prospective 
Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Re ́union. PLoS 
Med. 2008, 5, 413–423.  
  (3) Yergolkar, P. N.; Tandale, B. V.; Arankalle, V. A.; Sathe, P. S.; Sudeep, A. B.; Gandhe, 
S. S.; Gokhle, M. D.; Jacob, G. P.; Hundekar, S. L.; Mishra, A. C. Chikungunya Outbreaks 
Caused by African Genotype, India. Emerg. Infect. Dis. 2006, 12, 1580–1583. 
  
42
  (4) Lucas-Hourani, M.; Lupan, A.; Desprès, P.; Thoret, S.; Pamlard, O.; Dubois, J.; Guillou, 
C.; Tangy, F.; Vidalain, P. O.; Munier-Lehmann, H. A Phenotypic Assay to Identify 
Chikungunya Virus Inhibitors Targeting the Nonstructural Protein nsP2. J. Biomol. Screen. 2012, 
18, 172–179.   
  (5) Cavrini, F.; Gaibani, P.; Pierro, A. M.; Rossini, G.; Landini, M. P.; Sambri, V. 
Chikungunya: An Emerging and Spreading Arthropod-Borne Viral Disease. J. Infect. Dev. 
Ctries. 2009, 3, 744–752. 
  (6)  Pohjala, L.; Utt, A.; Varjak, M.; Lulla, A.; Merits, A.; Ahola, T.; Tammela, P. Inhibitors 
of Alphavirus Entry and Replication Identified with a Stable Chikungunya Replicon Cell Line 
and Virus-Based Assay. PLoS ONE 2011, 6, e28923.  
  (7)  Ozden, S.; Lucas-Hourani, M.; Ceccaldi, P. E.; Basak, A.; Valentine, M.; Benjannet, S.; 
Hamelin, J.; Jacob, Y.; Mamchaoui, K.; Mouly, V.; Despres, P.; Gessain, A.; Butler-Browne, G.; 
Chretien, M.; Tangy, F.; Vidalain, P. O.; Seidah, N. G. Inhibition of Chikungunya Virus 
Infection in Cultured Human Muscle Cells by Furin Inhibitors. J. Biol. Chem. 2008, 283,  
21899–21908. 
(8) Khan, M.; Dhanwani, R.; Patro, I. K.; Rao, P. V. L.; Parida, M. M. Cellular IMPDH 
Enzyme Activity is a Potential Target for the Inhibition of Chikungunya Virus Replication and 
Virus Induced Apoptosis in Cultured Mammalian Cells. Antiviral Res. 2011, 89, 1–8. 
  (9) Briolant, S.; Garin, D.; Scaramozzino, N.; Jouan, A.; Crance, J. M. In Vitro Inhibition of 
Chikungunya and Semliki Forest Viruses Replication by Antiviral Compounds: Synergistic 
Effect of Interferon-α and Ribavirin Combination. Antiviral Res. 2004, 61, 111–117. 
  
43
(10) Delogu, I.; Pastorino, B.; Baronti, C.; Nougairède, A.; Bonnet, E.; Lamballerie, X. D. In 
Vitro Antiviral Activity of Arbidol Against Chikungunya Virus and Characteristics of a Selected 
Resistant Mutant. Antiviral Res. 2011, 90, 99–107. 
(11) D’hooghe, M.; Mollet, K.; Vreese, R. D.; Jonckers, T. H. M.; Dams, G.; Kimpe, N. D. 
Design, Synthesis, and Antiviral Evaluation of Purine-β-lactam and Purine-aminopropanol 
Hybrids. J. Med. Chem. 2012, 55, 5637–5641.  
(12) Bassetto, M.; Burghgraeve, T. D.; Delang, L.; Massarotti, A.; Coluccia, A.; Zonta, N.; 
Gatti, V.; Colombano, G.; Sorba, G.; Silvestri, R.; Tron, G. C.; Neyts, J.; Leyssen, P.; Brancale, 
A. Computer-aided Identification, Design and Synthesis of a Novel Series of Compounds with 
Selective Antiviral Activity Against Chikungunya Virus. Antiviral Res. 2013, 98, 12–18. 
(13) Bourjot, M.; Leyssen, P.; Eydoux, C.; Guillemot, J. C.; Canard, B.; Rasoanaivo, P.; 
Gueritte, F.; Litaudon, M. Chemical Constituents of Anacolosa Pervilleana and Their Antiviral 
Activities. Fitoterapia 2012, 83, 1076–1080. 
(14) Lagoja, I. M.; Pyrimidine as Constituent of Natural Biologically Active Compounds. 
Chem. Biodiv. 2005, 2, 1–50.   
(15) Wang, X.; Zhang, J.; Huang, Y.; Wang, R.; Zhang, L.; Qiao, K.; Li, L.; Liu, C.; Ouyang, 
Y.; Xu, W.; Zhang, Z.; Zhang, L.; Shao, Y.; Jiang, S.; Ma, L.; Liu, J. Design, Synthesis, and 
Biological Evaluation of 1-[(2-Benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as Potent HIV-1 
Non-nucleoside Reverse Transcriptase Inhibitors with an Improved Drug Resistance Profile.  
J. Med. Chem. 2012, 55, 2242–2250.  
  
44
(16) Abdel–Aal, M. T.; Synthesis and Anti-Hepatitis B Activity of New Substituted Uracil 
and Thiouracil Glycosides.  Arch. Pharm. Res. 2010, 33, 797–805.  
(17) Kumar, R.; Semaine, W.; Johar, M.; Tyrrell, L. J.; Agrawal, B. Effect of Various 
Pyrimidines Possessing the 1-[(2-Hydroxy-1-(hydroxymethyl)ethoxy) methyl] Moiety, Able to 
Mimic Natural 2′-Deoxyribose, on Wild-type and Mutant Hepatitis B Virus Replication. J. Med. 
Chem. 2006, 49, 3693–3700. 
(18) Ordonez, P.; Hamasaki, T.; Isono, Y.; Sakakibara, N.; Ikejiri, M.; Maruyama, T.; Baba, 
M. Anti-Human Immunodeficiency Virus Type 1 Activity of Novel 6-Substituted 1-Benzyl-3-
(3,5-Dimethylbenzyl)Uracil Derivatives.  Antimicrob. Agents Chemother. 2012, 56, 2581–2589.  
(19) Wakeling, A. E.; Guy, S. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Barker, A. J.; 
Gibson, K. H. ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor 
Signaling with Potential for Cancer Therapy. Cancer Res. 2002, 62, 5749–5754.   
(20) Gawad, N. M. A.; Georgey, H. H.; Youssef, R. M.; Sayed, N. A. E. Design, Synthesis, 
and Anticonvulsant Activity of Novel Quinazolinone Analogues. Med. Chem. Res. 2011, 20, 
1280–1286. 
(21) Gökhan-Kelekçi, N.; Koyunoglu, S.; Yabanoglu, S.; Yelekçi, K.; Özgen, O.; Uçar, G.; 
Erol, K.; Kendi, E.; Yesilada, A. New Pyrazoline Bearing 4(3H)-Quinazolinone Inhibitors of 
Monoamine Oxidase: Synthesis, Biological Evaluation, and Structural Determinants of MAO-A 
 and MAO-B Selectivity. Bioorg. Med. Chem. 2009, 17, 675–689.  
(22) Rajput, C. S.; Singhal, S. Synthesis, Characterization, and Anti-Inflammatory Activity of 
Newer Quinazolinone Analogs. J. Pharm. 2012, 2013, Article ID 907525.  
  
45
(23) Xu, Z.; Zhang, Y.; Fu, H.; Zhong, H.; Hong, K.; Zhu, W. Antifungal Quinazolinones 
from Marine-derived Bacillus Cereus and Their Preparation. Bioorg. Med. Chem. Lett. 2011, 21, 
4005–4007.  
(24) Wang, Z.; Wang, M.; Yao, X.; Li, Y.; Tan, J.; Wang, L.; Qiao, W.; Geng, Y.; Liu, Y.; 
Wang, Q. Design, Synthesis and Antiviral Activity of Novel Quinazolinones.  Eur. J. Med. 
Chem. 2012, 53, 275–282. 
(25) El-Sharief, A. M. S.; Ammar, Y. A.; Zahran, M. A.; Ali, A. H.; El-Gaby, M. S. A. 
Aminoacids in the Synthesis of Heterocyclic Systems:  The Synthesis of Triazinoquinazolinones, 
Triazepinoquinazolinones and Triazocinoquinazolinones of Potential Biological Interest. 
Molecules 2001, 6, 267–278. 
(26) Patil, A.; Ganguly, S.; Surana, S. Synthesis and Antiulcer Activity of  
2-[5-Substituted-1-H-benzo(d)imidazol-2-ylsulfinyl]methyl-3-substituted quinazoline-4-
(3H)ones. J. Chem. Sci. 2010, 122, 443–450.  
(27) Farag, A. A.; Khalifa, E. M.; Sadik, N. A.; Abbas, S. Y.; Al-Sehemi, A. G.; Ammar, Y. 
A. Synthesis, Characterization, and Evaluation of Some Novel 4(3H)-Quinazolinone Derivatives 
as Anti-Inflammatory and Analgesic Agents. Med. Chem. Res. 2013, 22, 440–452. 
(28) Refaie, F. M.; Esmat, A. Y.; Gawad, S. M. A.; Ibrahim, A. M.; Mohamed, M. A. The 
Antihyperlipidemic Activities of 4(3H)-Quinazolinone and Two Halogenated Derivatives in 
Rats. Lipids Health Dis. 2005, 4, 22–32. 
  
46
(29) El-Hashash, M. A.; Rizk, S. A.; El-Bassiouny, F. A. Uses of 2-Ethoxy-4(3H) 
quinazolinone in Synthesis of Quinazoline and Quinazolinone Derivatives of Antimicrobial 
Activity: The Solvent Effect. Glob. J. Health. Sci. 2012, 4, 162–173.  
(30) Baek, D. J.; Kang, T. B.; Kim, H. J. Synthesis of Nonclassical Quinazolinone Antifolates 
as Thymidylate Synthase Inhibitors and Their Antitumor Activity In Vitro.  
Bull. Korean Chem. Soc. 2004, 25, 1898–1906. 
(31) Iwashita, A.; Hattori, K.; Yamamoto, H.; Ishida, J.; Kido, Y.; Kamijo, K.; Murano, K.; 
Miyake, H.; Kinoshita, T.; Warizaya, M.; Ohkubo, M.; Matsuoka, N.; Mutoh, S. Discovery of 
Quinazolinone and Quinoxaline derivatives as Potent and Selective Poly(ADP-ribose) 
Polymerase-1/2 Inhibitors. FEBS Lett. 2005, 579, 1389–1393.  
(32) Srivastava, S. K.; Kumar, V.; Agarwal, S. K.; Mukherjee, R.; Burman, A. C. Synthesis of 
Quinazolines as Tyrosine Kinase Inhibitors. Anti-Cancer Agents Med. Chem. 2009, 9, 246–275.  
(33) Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, 
M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. 
Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of 
Dipeptidyl Peptidase IV. J. Med. Chem. 2007, 50, 2297–2300.  
(34) Horton, D. A.; Bourne, G. T.; Smythe, M. L. The Combinatorial Synthesis of Bicyclic 
Privileged Structures or Privileged Substructures. Chem. Rev. 2003, 103, 893−930. 
(35) Kostova, I.; Raleva, S.; Genova, P.; Argirova, R. Structure-Activity Relationships of 
Synthetic Coumarins as HIV-1 Inhibitors.  Bioinorg. Chem. Appl. 2005, 2006, Article ID 68274.  
  
47
(36) Pochet, L.; Frederick, R.; Masereel, B.; Coumarin and Isocoumarin as Serine Protease 
Inhibitors. Curr. Pharm. Des. 2004, 10, 3781–3796. 
(37) Hwu, J. R.; Singha, R.; Hong, S. C.; Chang, Y. H.; Das, A. R.; Vliegen, I.; Clercq, E. D.; 
Neyts, J. Synthesis of New Benzimidazole–Coumarin Conjugates as Anti-Hepatitis C Virus 
Agents. Antiviral Res. 2008, 77, 157–162. 
(38) Neyts, J.; Clercq, E. D.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, 
S. C.; Tsay, S. C.; Hsu, M. H.; Hwu, J. R. Structure-Activity Relationship of New Anti-Hepatitis 
C Virus Agents: Heterobicycle–Coumarin Conjugates. J. Med. Chem. 2009, 52, 1486–1490. 
(39) Hwu, J. R.; Lin, S. Y.; Tsay, S. C.; Clercq, E. D.; Leyssen, P.; Neyts, J. Coumarin-Purine 
Ribofuranoside Conjugates as New Agents against Hepatitis C Virus. J. Med. Chem. 2011, 54, 
2114–2126. 
(40) Tsay, S. C.; Hwu, J. R.; Singha, R.; Huang, W. C.; Chang, Y. H.; Hsu, M. H.; Shieh, F. 
K.; Lin, C. C.; Hwang, K. C.; Horng, J. C.; Clercq, E. D.; Vliegen, I.; Neyts, J. Coumarins 
Hinged Directly on Benzimidazoles and Their Ribofuranosides to Inhibit Hepatitis C Virus. Eur. 
J. Med. Chem. 2013, 63, 290–298. 
(41) Hwu, J. R.; Lin, S. Y.; Tsay, S. C.; Singha, R.; Pal, B. K.; Leyssen, P.; Neyts, J. 
Development of New Sulfur-Containing Conjugated Compounds as Anti-HCV Agents. 
Phosphorus, Sulfur, Silicon Relat. Elem. 2011, 186, 1144–1152. 
(42) Roush, W. R.; Gwaltney II, S. L.; Cheng, J.; Scheidt, K. A.; McKerrow, J. H.; Hansell, E. 
Vinyl Sulfonate Esters and Vinyl Sulfonamides: Potent, Irreversible Inhibitors of Cysteine 
Proteases. J. Am. Chem. Soc. 1998, 120, 10994–10995. 
  
48
(43) Shenai, B. R.; Lee, B. J.; Alvarez-Hernandez, A.; Chong, P. Y.; Emal, C. D.; Neitz, R. J.; 
Roush, W. R.; Rosenthal, P. J. Structure-Activity Relationships for Inhibition of Cysteine 
Protease Activity and Development of Plasmodium Falciparum by Peptidyl Vinyl Sulfones. 
Antimicrob. Agents Chemother. 2003, 47, 154–160. 
(44) Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Irreversible Inhibitors of Serine, 
Cysteine, and Threonine Proteases. Chem. Rev. 2002, 102, 4639–4750. 
(45) Stevenson, R. J.; Denny. W. A.; Tercel, M.; Pruijn, F. B.; Ashoorzadeh, A. Nitro seco 
Analogues of the Duocarmycins Containing Sulfonate Leaving Groups as Hypoxia-Activated 
Prodrugs for Cancer Therapy. J. Med. Chem. 2012, 55, 2780−2802.  
(46) Udommaneethanakit, T.; Rungrotmongkol, T.; Frecer, V.; Seneci, P.; Stanislav, M.; 
Bren, U. Drugs against Avian Influenza A Virus: Design of Novel Sulfonate Inhibitors of 
Neuraminidase N1. Curr. Pharm. Des. 2013, 19, 10.2174/13816128113199990629.  
(47) Adam, G. C.; Sorensen, E. J.; Cravatt, B. F. Proteomic Profiling of Mechanistically 
Distinct Enzyme Classes Using a Common Chemotype. Nat. Biotechnol. 2002, 20, 805−809.  
(48) Evans, M. J.; Cravatt, B. F. Mechanism-Based Profiling of Enzyme Families. Chem. Rev. 
2006, 106, 3279−3301. 
(49) Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering Potent and Selective 
Reversible Inhibitors of Enzymes in Complex Proteomes. Nat. Biotechnol. 2003, 21, 687−691. 
(50) Opanasenko, M.; Shamzhy, M.; Cejka, J. Solid Acid Catalysts for Coumarin Synthesis by 
the Pechmann Reaction: MOFs versus Zeolites. ChemCatChem, 2013, 5, 1024 1031. 
  
49
(51) Somers, F.; Ouedraogo, R.; Antoine, M. H.; Tullio, P. D Becker, B.; Fontaine, J.; Damas, 
J.; Dupont, L.; Rigo, B.; Delarge, J.; Lebrun, P.; Pirotte, B. Original 2-Alkylamino-6-
halogenoquinazolin-4(3H)-ones and KATP Channel Activity. J. Med. Chem. 2001, 44, 
2575−2585. 
(52) Hann, M. M.; Keserü, G. M. Finding the Sweet Spot: The Role of Nature and Nurture in 
Medicinal Chemistry. Nat. Rev. 2012, 11, 355−365.  
(53) Kraszni, M.; Banyai, I.; Noszal, B. Determination of Conformer-Specific Partition 
Coefficients in Octanol/Water Systems. J. Med. Chem. 2003, 46, 2241-2245. 
(54) Leeson, P. Chemical Beauty Contest. Nature 2012, 481, 455-456. 
(55) Pisani, L.; Barletta, M.; Soto-Otero, R.; Nicolotti, O.; Mendez-Alvarez, E.; Catto, M.; 
Introcaso, A.; Stefanachi, A.; Cellamare, S.; Altomare, C.; Carotti, A. Discovery, Biological 
Evaluation, and Structure−Activity and −Selectivity Relationships of 6′-Substituted (E) 2-
(Benzofuran-3(2H) ylidene) N methylacetamides, a Novel Class of Potent and Selective 
Monoamine Oxidase Inhibitors. J. Med. Chem. 2013, 56, 2651−2664. 
(56) Pisani, L.; Muncipinto, G.; Miscioscia, T. F.; Nicolotti, O.; Leonetti, F.; Catto, M.; 
Caccia, C.; Salvati, P.; Soto-Otero, R.; Mendez-Alvarz, E.; Passeleu, C.; Carotti, A. Discovery of 
a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and 
Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-
chromen-2-one methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and 
Orally Active Monoamine Oxidase B Inhibitor. J. Med. Chem. 2009, 52, 6685−6706. 
  
50
(57) Stefanachi, A.; Favia, A. D.; Nicolotti, O.; Leonetti, F.; Pisani, L.; Catto, M.; Zimmer, C.; 
hartmann, R. W.; Carotti, A. Design, Synthesis, and Biological Evaluation of Imidazolyl 
Derivatives of 4,7-Disubstituted Coumarins as Aromatase Inhibitors Selective Over 17-α-
Hydroxylase/C17−20 Lyase. J. Med. Chem. 2011, 54, 1613−1625.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51
 
 
TOC Graphic 
 
 
 
 
 
 
 
 
 
 
 
 
N
NH
O
S
O
O
O
X
Y Y
R3
critical
conjugation
essential
enhancement
X = S ,Y= O CHIKV Inhibition
